<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by MDD - e-reporting v3 -->
<!-- Created by MDD - Management Digital Data AG, Switzerland -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nvs="http://novartis.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ns0="http://www.novartis.com/custom-units">
  <link:schemaRef xlink:type="simple" xlink:href="nvs-20201231.xsd" />
  <xbrli:context id="AR_I-CurrentYearEnd-2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYearStart-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-4-April-9_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsUSDMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:BorrowingsUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsEURMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:BorrowingsEURMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AlconBrandNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AlconBrandNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember_srt-2020LitigationCaseAxis_nvs-2020Q4TennesseeClassActionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EnoxaparinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nvs:TennesseeClassActionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AmiodaroneMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AmiodaroneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ReclastAclastaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ReclastAclastaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TaxotereMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TaxotereMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EnoxaparinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfDiscountRatesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NAGAndNovartisPharmaSpAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NAGAndNovartisPharmaSpAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPharmaKKMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPharmaKKMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommitmentForRepurchaseOfOwnSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommitmentForRepurchaseOfOwnSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AmblyotechInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AmblyotechInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoalesceProductDevelopmentLimitedCambridgeCambsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenJapanK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenJapanK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:RocheHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoalesceProductDevelopmentLimitedCambridgeCambsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOptogeneticsResearchInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOptogeneticsResearchInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozManufacturingInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozManufacturingInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCusiS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCusiS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisInc.BannockburnILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisInc.BannockburnILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoStimPharmaceuticalsInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoStimPharmaceuticalsInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:RocheHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZiarcoGroupLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZiarcoGroupLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUSFoundationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiosciencesPeruS.A.LimaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiosciencesPeruS.A.LimaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZAOSandozMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZAOSandozMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdKemptonParkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdKemptonParkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisForschungsstiftungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerKaderausbildungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerMenschUndUmweltBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOphthalmicsAGFribourgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOphthalmicsAGFribourgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHOberhachingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHOberhachingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TabrectaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KesimptaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4FHoffmanLaRocheAGAndRocheSpAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:FHoffmanLaRocheAGAndRocheSpAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-23</xbrli:startDate>
      <xbrli:endDate>2019-11-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-06</xbrli:startDate>
      <xbrli:endDate>2020-01-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-07</xbrli:startDate>
      <xbrli:endDate>2019-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-11</xbrli:startDate>
      <xbrli:endDate>2019-11-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-31</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InvestmentsInSubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InvestmentsInSubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:GoodwillFromAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:GoodwillFromAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4LifeExpectancyMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Increase1YearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrDanielVasellaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrDanielVasellaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPensionFundMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPensionFundMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4USCommercialPaperProgramsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:USCommercialPaperProgramsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:JPCommercialPaperProgramsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentAssetsMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_nvs-2020Q4IncomeStatementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ImpactLocationAxis">nvs:IncomeStatementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_ifrsfull-2019EquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ImpactLocationAxis">ifrs-full:EquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GSKConsumerHealthcareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-27</xbrli:startDate>
      <xbrli:endDate>2018-03-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GSKConsumerHealthcareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AAA-Dec2020_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Avexis_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-15</xbrli:startDate>
      <xbrli:endDate>2018-05-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-21</xbrli:startDate>
      <xbrli:endDate>2018-12-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SparkTherapeuticsInc.Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SparkTherapeuticsInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLeveragedShareSavingsPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLeveragedShareSavingsPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationSpecialShareAwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationSpecialShareAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTechnologyLLCInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="CHFPerShares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CHF</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CHF">
    <xbrli:measure>iso4217:CHF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Year">
    <xbrli:measure>ns0:year</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="JPY">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="VEF">
    <xbrli:measure>iso4217:VEF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="VND">
    <xbrli:measure>iso4217:VND</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="ILS">
    <xbrli:measure>iso4217:ILS</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PHP">
    <xbrli:measure>iso4217:PHP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="GBP">
    <xbrli:measure>iso4217:GBP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CAD">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="TWD">
    <xbrli:measure>iso4217:TWD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="THB">
    <xbrli:measure>iso4217:THB</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="TRY">
    <xbrli:measure>iso4217:TRY</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UAH">
    <xbrli:measure>iso4217:UAH</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="AED">
    <xbrli:measure>iso4217:AED</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PKR">
    <xbrli:measure>iso4217:PKR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PEN">
    <xbrli:measure>iso4217:PEN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PLN">
    <xbrli:measure>iso4217:PLN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="RON">
    <xbrli:measure>iso4217:RON</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="RUB">
    <xbrli:measure>iso4217:RUB</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="SAR">
    <xbrli:measure>iso4217:SAR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="SGD">
    <xbrli:measure>iso4217:SGD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="ZAR">
    <xbrli:measure>iso4217:ZAR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="KRW">
    <xbrli:measure>iso4217:KRW</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="SEK">
    <xbrli:measure>iso4217:SEK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="DZD">
    <xbrli:measure>iso4217:DZD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="ARS">
    <xbrli:measure>iso4217:ARS</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="AUD">
    <xbrli:measure>iso4217:AUD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="BDT">
    <xbrli:measure>iso4217:BDT</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="BRL">
    <xbrli:measure>iso4217:BRL</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CLP">
    <xbrli:measure>iso4217:CLP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="HKD">
    <xbrli:measure>iso4217:HKD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="COP">
    <xbrli:measure>iso4217:COP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="HRK">
    <xbrli:measure>iso4217:HRK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CZK">
    <xbrli:measure>iso4217:CZK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="DKK">
    <xbrli:measure>iso4217:DKK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="EGP">
    <xbrli:measure>iso4217:EGP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="HUF">
    <xbrli:measure>iso4217:HUF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="INR">
    <xbrli:measure>iso4217:INR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="IDR">
    <xbrli:measure>iso4217:IDR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MYR">
    <xbrli:measure>iso4217:MYR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MXN">
    <xbrli:measure>iso4217:MXN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MAD">
    <xbrli:measure>iso4217:MAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="NZD">
    <xbrli:measure>iso4217:NZD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="NOK">
    <xbrli:measure>iso4217:NOK</xbrli:measure>
  </xbrli:unit>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">8782000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">7558000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">-1224000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">354000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-289000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">47000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-25000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7952000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">-2042000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">43000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5910000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-83000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">6805000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">124000000</nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7909000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5867000000</ifrs-full:DeferredTaxLiabilities>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2986000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9000000</nvs:ValueOfTaxLossCarryforwardsExpired>
  <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">8000000</nvs:ValueOfTaxLossCarryforwardsExpired>
  <nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">4300000000</nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">5200000000</nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:ProvisionForIncomeTaxesOnUnremittedEarnings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-9">0</nvs:ProvisionForIncomeTaxesOnUnremittedEarnings>
  <nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">0.13</nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">0.13</nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-234000000</nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">90379000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">1.00</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">77701000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">1.00</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="AR_D-Transaction-Alcon-3-April-8" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">7000000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">47445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">44751000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:AmountBorrowedUnderTheCreditFacility contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-9">7000000000</nvs:AmountBorrowedUnderTheCreditFacility>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2005000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3485000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">295000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
  <nvs:NoncurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3190000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
  <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">66000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">7000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">8000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">339000000</ifrs-full:CashOutflowForLeases>
  <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">15000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
  <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">51000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">273000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1993000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1809000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">139000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">44000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">137000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3550000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">2531000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">342000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">10224000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">22000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">1000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">60000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">381000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <nvs:FinancialAndOtherAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8000000</nvs:FinancialAndOtherAssets>
  <nvs:FinancialAndOtherAssets contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">19000000</nvs:FinancialAndOtherAssets>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">195000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">20000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">4000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">90000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">1112000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">107000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">2874000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">14000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <nvs:TradePayablesAndOtherLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">178000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:TradePayablesAndOtherLiabilities contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">627000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:IdentifiableAssetsAcquired contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7669000000</nvs:IdentifiableAssetsAcquired>
  <nvs:IdentifiableAssetsAcquired contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3938000000</nvs:IdentifiableAssetsAcquired>
  <nvs:IdentifiableAssetsAcquired contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">11000000000</nvs:IdentifiableAssetsAcquired>
  <nvs:AcquiredCashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">1112000000</nvs:AcquiredCashAndCashEquivalents>
  <ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">26000000</ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">186000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">4084000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">10173000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">4124000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">13946000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">98000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">0</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1833000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1876000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1506000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-9957000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-3760000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-13683000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-127000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1159000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-1001000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="0">3000</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">500000000</nvs:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate>
  <nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">358000000</nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:MajorPlansPercentageInGroupDBOPensions contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.95</nvs:MajorPlansPercentageInGroupDBOPensions>
  <nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.81</nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">5232000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-467000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">80000000</nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears>
  <nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">25000000</nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">53000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">82000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">48659000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">47498000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">44833000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1239000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1179000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1266000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">15121000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">14425000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14510000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">34777000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">34252000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">31589000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">14197000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">14369000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13717000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8980000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9402000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">8489000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1742000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2031000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1629000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3190000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3426000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2609000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">10152000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9086000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">8403000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">659000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6438000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">869000000</ifrs-full:InterestExpense>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">850000000</ifrs-full:InterestExpense>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">932000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-78000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">45000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">186000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">9878000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">8940000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14095000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1793000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1295000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8071000000</ifrs-full:ProfitLossFromContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">7147000000</ifrs-full:ProfitLossFromContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12800000000</ifrs-full:ProfitLossFromContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-101000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-186000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-186000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8071000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11737000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12614000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11732000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12611000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.55</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">3.12</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.52</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">2.00</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">-0.08</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:BasicEarningsLossPerShare contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.55</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:BasicEarningsLossPerShare contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">5.12</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:BasicEarningsLossPerShare contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.44</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.52</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">3.08</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.46</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">1.98</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">-0.08</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:DilutedEarningsLossPerShare contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.52</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShare contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">5.06</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShare contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.38</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:ParValuePerShare contextRef="AR_I-CurrentYearEnd" unitRef="CHFPerShares" decimals="2">0.50</ifrs-full:ParValuePerShare>
  <nvs:NumberOfReportableSegments contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">2</nvs:NumberOfReportableSegments>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">12263000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">12069000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1676000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1677000000</ifrs-full:RightofuseAssets>
  <ifrs-full:Goodwill contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">29999000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">26524000000</ifrs-full:Goodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">36809000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28787000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9632000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8644000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8214000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2901000000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2518000000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">892000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">738000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">102386000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">88866000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7131000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5982000000</ifrs-full:Inventories>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8217000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8301000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTaxAssetsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">239000000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:CurrentTaxAssetsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">254000000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:OtherCurrentFinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1905000000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:OtherCurrentFinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">334000000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9658000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">11112000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2523000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2680000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">29673000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
  <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28663000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
  <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">841000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">29673000000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">29504000000</ifrs-full:CurrentAssets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">132059000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">118370000000</ifrs-full:Assets>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">913000000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">936000000</ifrs-full:IssuedCapital>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">53000000</ifrs-full:TreasuryShares>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">80000000</ifrs-full:TreasuryShares>
  <ifrs-full:OtherReserves contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">55738000000</ifrs-full:OtherReserves>
  <ifrs-full:OtherReserves contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">54618000000</ifrs-full:OtherReserves>
  <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">56598000000</ifrs-full:EquityAttributableToOwnersOfParent>
  <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">55474000000</ifrs-full:EquityAttributableToOwnersOfParent>
  <ifrs-full:NoncontrollingInterests contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">68000000</ifrs-full:NoncontrollingInterests>
  <ifrs-full:NoncontrollingInterests contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">77000000</ifrs-full:NoncontrollingInterests>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">56666000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">55551000000</ifrs-full:Equity>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">26259000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">20353000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1719000000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1703000000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7422000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">6934000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">6632000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">42334000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">34555000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">5403000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5424000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9785000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7031000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">286000000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">246000000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2458000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2194000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">15127000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">13338000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">33059000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28233000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">31000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">33059000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28264000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">75393000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">62819000000</ifrs-full:Liabilities>
  <ifrs-full:EquityAndLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">132059000000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EquityAndLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">118370000000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">9881000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9122000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1486000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">490000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">463000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">719000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">47000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">214000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">241000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">703000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">793000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">816000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">464000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">28000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">218000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">39000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">33000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">31000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">16378000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">14272000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13111000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2437000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">924000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">638000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-291000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">199000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">576000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">13650000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">13547000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13049000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">78000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1223000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">13650000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">13625000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14272000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1275000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1379000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1254000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">88000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">857000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">102000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1310000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">878000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1394000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">380000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">973000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">823000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">230000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">302000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">205000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">723000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1152000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">165000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">61000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">60000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">39000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">9000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-7000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-6000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12854000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1900000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">228000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2440000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">492000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2561000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">472000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-13055000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1067000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-4590000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-13182000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-2226000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-5591000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2842000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5533000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2036000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">748000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">201000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">700000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">93000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2856000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3195000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">366000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1582000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1687000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">19000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-147000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">56000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">67000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-2158000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-16884000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-4077000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-50000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3257000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-167000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-2208000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-13627000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-4244000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1740000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-2228000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">4437000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">286000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">69000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-26000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1454000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-2159000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">4411000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">8860000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">13271000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">91000000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">245000000</ifrs-full:RevenueFromInterest>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">335000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">38000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">354000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">492000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">292000000</ifrs-full:RevenueFromInterest>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-6000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">521000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">24481000000</ifrs-full:NetDebt>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">15938000000</ifrs-full:NetDebt>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">81147000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">71489000000</nvs:NetOperatingAssets>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1265000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1474000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">66808000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">55311000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1425000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">767000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-31000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-55000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">11563000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">11446000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">36044000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">27384000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9880000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8061000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">835000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">734000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">300000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">147000000</ifrs-full:RevenueFromRoyalties>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">50000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">231000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">54000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">67000000</nvs:OtherRevenueOther>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">877000000</nvs:ProfitSharingIncome>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">617000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">565000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">5956000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">708000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
  <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">714000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
  <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">877000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">67000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">94000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">70000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">55000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">18000000</ifrs-full:RevenueFromDividends>
  <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">12000000</ifrs-full:RevenueFromDividends>
  <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1000000</ifrs-full:RevenueFromDividends>
  <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">52000000</ifrs-full:OtherFinanceCost>
  <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">52000000</ifrs-full:OtherFinanceCost>
  <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">39000000</ifrs-full:OtherFinanceCost>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-135000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-160000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-68000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">188000000</ifrs-full:RevenueFromRoyalties>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">28000000</nvs:OtherRevenueOther>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">173000000</nvs:MilestoneIncome>
  <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">256000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
  <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:BorrowingCostsCapitalised>
  <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">220000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
  <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4000000</ifrs-full:BorrowingCostsCapitalised>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">330000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:DeferredCompensationPlansAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">471000000</nvs:DeferredCompensationPlansAssets>
  <nvs:DeferredCompensationPlansAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">414000000</nvs:DeferredCompensationPlansAssets>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">202000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">148000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">219000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
  <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">176000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
  <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">8500000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
  <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">8500000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
  <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-8">8300000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
  <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">752000000</ifrs-full:InventoryWritedown2011>
  <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">603000000</ifrs-full:InventoryWritedown2011>
  <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">218000000</ifrs-full:ReversalOfInventoryWritedown>
  <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">216000000</ifrs-full:ReversalOfInventoryWritedown>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">544000000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">508000000</ifrs-full:CurrentValueAddedTaxReceivables>
  <nvs:WithholdingTaxRecoverable contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">73000000</nvs:WithholdingTaxRecoverable>
  <nvs:WithholdingTaxRecoverable contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">108000000</nvs:WithholdingTaxRecoverable>
  <nvs:CurrentPrepaidExpensesThirdParty contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">943000000</nvs:CurrentPrepaidExpensesThirdParty>
  <nvs:CurrentPrepaidExpensesThirdParty contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">898000000</nvs:CurrentPrepaidExpensesThirdParty>
  <nvs:ReceivablesAssociatedCompanies contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1000000</nvs:ReceivablesAssociatedCompanies>
  <nvs:OtherReceivablesAndCurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">963000000</nvs:OtherReceivablesAndCurrentAssets>
  <nvs:OtherReceivablesAndCurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1165000000</nvs:OtherReceivablesAndCurrentAssets>
  <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3538000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
  <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3469000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
  <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">637000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
  <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">546000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
  <nvs:OtherPostemploymentBenefits contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">543000000</nvs:OtherPostemploymentBenefits>
  <nvs:OtherPostemploymentBenefits contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">612000000</nvs:OtherPostemploymentBenefits>
  <nvs:EnvironmentalRemediationProvisionNoncurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">642000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
  <nvs:EnvironmentalRemediationProvisionNoncurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">592000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">181000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">200000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:ContingentConsiderationNonCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">984000000</nvs:ContingentConsiderationNonCurrent>
  <nvs:ContingentConsiderationNonCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">958000000</nvs:ContingentConsiderationNonCurrent>
  <ifrs-full:OtherNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">409000000</ifrs-full:OtherNoncurrentLiabilities>
  <ifrs-full:OtherNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">255000000</ifrs-full:OtherNoncurrentLiabilities>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">761000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-10000000</nvs:EnvironmentalProvisionPayments>
  <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-30000000</nvs:EnvironmentalProvisionPayments>
  <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-48000000</nvs:EnvironmentalProvisionPayments>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">27000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">83000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">21000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">82000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">124000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">7000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">50000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
  <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
  <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-7000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">809000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">714000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">692000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvisionCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">167000000</nvs:EnvironmentalProvisionCurrent>
  <nvs:EnvironmentalProvisionCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">122000000</nvs:EnvironmentalProvisionCurrent>
  <nvs:EnvironmentalProvisionCurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">58000000</nvs:EnvironmentalProvisionCurrent>
  <nvs:EnvironmentalRemediationProvisionNoncurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">634000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
  <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">749000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
  <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">471000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
  <ifrs-full:ShorttermRestructuringProvision contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">459000000</ifrs-full:ShorttermRestructuringProvision>
  <ifrs-full:ShorttermRestructuringProvision contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">438000000</ifrs-full:ShorttermRestructuringProvision>
  <ifrs-full:AccrualsClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1167000000</ifrs-full:AccrualsClassifiedAsCurrent>
  <ifrs-full:AccrualsClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1046000000</ifrs-full:AccrualsClassifiedAsCurrent>
  <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">732000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
  <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">653000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
  <ifrs-full:CurrentInterestPayable contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">133000000</ifrs-full:CurrentInterestPayable>
  <ifrs-full:CurrentInterestPayable contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">98000000</ifrs-full:CurrentInterestPayable>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">6256000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5595000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2286000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2464000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">56000000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">114000000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">269000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
  <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">326000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
  <nvs:ContingentConsiderationCurrentPortion contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">62000000</nvs:ContingentConsiderationCurrentPortion>
  <nvs:ContingentConsiderationCurrentPortion contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">78000000</nvs:ContingentConsiderationCurrentPortion>
  <ifrs-full:OtherCurrentPayables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">716000000</ifrs-full:OtherCurrentPayables>
  <ifrs-full:OtherCurrentPayables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">764000000</ifrs-full:OtherCurrentPayables>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">234000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">19294000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-151000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">19773000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-99000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">5262000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-10000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">19348000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-220000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">20001000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-104000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1411000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1871000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">895000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-478000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1234000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-902000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">738000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">758000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">673000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-947000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-805000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-746000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-543000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-382000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-387000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">137000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-980000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-544000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-324000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">553000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">252000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">229000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-160000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">316000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">211000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1167000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">941000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
  <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
  <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
  <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-2000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">4672000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-129000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">18567000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-98000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">19052000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-332000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <nvs:NoncurrentFinancialAssetsEquityInvestments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1524000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
  <nvs:NoncurrentFinancialAsstetsDebtSecurities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">33000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
  <nvs:NoncurrentFinancialAssetsFundInvestments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">233000000</nvs:NoncurrentFinancialAssetsFundInvestments>
  <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1979000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
  <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1790000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
  <nvs:LongTermReceivablesFromFinanceSubleases contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">66000000</nvs:LongTermReceivablesFromFinanceSubleases>
  <ifrs-full:OtherNoncurrentReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">104000000</ifrs-full:OtherNoncurrentReceivables>
  <nvs:ContingentConsiderationReceivable contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">399000000</nvs:ContingentConsiderationReceivable>
  <ifrs-full:NoncurrentLoansAndReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">159000000</ifrs-full:NoncurrentLoansAndReceivables>
  <nvs:MarketableSecurities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">61000000</nvs:MarketableSecurities>
  <nvs:Commodities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">110000000</nvs:Commodities>
  <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">61000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
  <ifrs-full:DerivativeFinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">102000000</ifrs-full:DerivativeFinancialAssets>
  <ifrs-full:Cash contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3247000000</ifrs-full:Cash>
  <ifrs-full:CashEquivalents contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7865000000</ifrs-full:CashEquivalents>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">22167000000</ifrs-full:BondsIssued>
  <nvs:LiabilitiesToBanksAndOtherInstitutions contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">188000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
  <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2002000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
  <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.002</nvs:AverageInterestRateOnLoansReceived>
  <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">0.82</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
  <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.024</nvs:AverageInterestRateOnBorrowings>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">28532000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">43000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-29000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-555000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-94000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-482000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">28531000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">22355000000</ifrs-full:Borrowings>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1169000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
  <nvs:InterestBearningAccountsOfAssociatesPayableOnDemand contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1836000000</nvs:InterestBearningAccountsOfAssociatesPayableOnDemand>
  <ifrs-full:ShorttermBorrowings contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">719000000</ifrs-full:ShorttermBorrowings>
  <ifrs-full:CommercialPapersIssued contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2289000000</ifrs-full:CommercialPapersIssued>
  <ifrs-full:DerivativeFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">185000000</ifrs-full:DerivativeFinancialLiabilities>
  <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.004</nvs:WeightedAverageInterestRateAssociates>
  <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.005</nvs:WeightedAverageInterestRateAssociates>
  <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.129</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">351000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-42000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">10000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-116000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-118000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">52000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">107000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1230000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">220000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-6000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">487000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1369000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">340000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">126000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">214000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">13</nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers>
  <nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="0">15</nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers>
  <nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="0">17</nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers>
  <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="0">13</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
  <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="0">13</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
  <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">166000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
  <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">64000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
  <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">92000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
  <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">427000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
  <nvs:AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">104000000</nvs:AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10>
  <nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">260000000</nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10>
  <nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-324000000</nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10>
  <nvs:LongtermFinancialDebtWithACarryingAmount contextRef="AR_I-CurrentYearEnd" unitRef="EUR" decimals="-8">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
  <nvs:LongtermFinancialDebtWithACarryingAmount contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">2300000000</nvs:LongtermFinancialDebtWithACarryingAmount>
  <nvs:LongtermFinancialDebtWithACarryingAmount contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-8">2100000000</nvs:LongtermFinancialDebtWithACarryingAmount>
  <nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">44000000</nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
  <nvs:NetInvestmentHedgeRecognizedInTheIncomeStatement contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">0</nvs:NetInvestmentHedgeRecognizedInTheIncomeStatement>
  <nvs:BorrowingsCommercialPaperNumberOfPrograms contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="0">3</nvs:BorrowingsCommercialPaperNumberOfPrograms>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">4300000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-8">2300000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCreditFacilityCommitted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-9">6000000000</nvs:BorrowingsCreditFacilityCommitted>
  <nvs:VAREstimateConfidenceInterval contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.95</nvs:VAREstimateConfidenceInterval>
  <nvs:MaximumMarginPercentageImpactOfCommodityPriceChange contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="2">0.10</nvs:MaximumMarginPercentageImpactOfCommodityPriceChange>
  <nvs:MaximumHoldingInUnrelatedCompany contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="2">0.05</nvs:MaximumHoldingInUnrelatedCompany>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1111000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1158000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">5745000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">5728000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6390000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6385000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">-6647000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1046000000</nvs:ContingentConsiderationLiabilities>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">-5434000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1036000000</nvs:ContingentConsiderationLiabilities>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">355000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">89000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">31000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">187000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <ifrs-full:WeightedAverageShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-6">2291000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-6">2319000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-6">28000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-6">25000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-6">2296000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-6">2319000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-6">2344000000</ifrs-full:AdjustedWeightedAverageShares>
  <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">0</nvs:OptionsExcludedFromTheCalculation>
  <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="0">0</nvs:OptionsExcludedFromTheCalculation>
  <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="0">0</nvs:OptionsExcludedFromTheCalculation>
  <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">273000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">30200000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">24800000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">26500000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">2600000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">46300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">45200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">47300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">79200000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">72600000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">76300000</ifrs-full:KeyManagementPersonnelCompensation>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1588000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">61000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">-24000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2000000</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12000000</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">352000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">315000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2937000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">304000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-60000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-47000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">393000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-514000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-346000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11401000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11527000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12208000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11403000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11525000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12210000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-406000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaid>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1973000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">434000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">263000000</nvs:OtherShareSales>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">756000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">79000000</nvs:TransactionCostsRecordedInEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">9000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">38000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-7803000000</ifrs-full:ChangesInEquity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-210000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5511000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">210000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">833000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">18000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">189000000</nvs:TaxesOnTreasuryShares>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-34671000000</ifrs-full:ChangesInEquity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3330000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3056000000</ifrs-full:PurchaseOfTreasuryShares>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-32000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-10286000000</ifrs-full:ChangesInEquity>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">969000000</ifrs-full:IssuedCapital>
  <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-25000000</nvs:IssuedCapitalMovement>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">944000000</ifrs-full:IssuedCapital>
  <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-8000000</nvs:IssuedCapitalMovement>
  <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-23000000</nvs:IssuedCapitalMovement>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">100000000</ifrs-full:TreasuryShares>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">69000000</ifrs-full:TreasuryShares>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">869000000</nvs:OutstandingShareCapital>
  <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6000000</nvs:OutstandingShareCapitalMovement>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">875000000</nvs:OutstandingShareCapital>
  <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-19000000</nvs:OutstandingShareCapitalMovement>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">856000000</nvs:OutstandingShareCapital>
  <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">4000000</nvs:OutstandingShareCapitalMovement>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">860000000</nvs:OutstandingShareCapital>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd-3" unitRef="Shares" decimals="-5">2317500000</ifrs-full:NumberOfSharesOutstanding>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-60300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-6300000</nvs:ShareMovements>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd" unitRef="Shares" decimals="-5">2256800000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd-1" unitRef="Shares" decimals="-5">2265000000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd-2" unitRef="Shares" decimals="-5">2311200000</ifrs-full:NumberOfSharesOutstanding>
  <nvs:StockRepurchaseProgramAuthorizedAmount1 contextRef="AR_I-CurrentYearEnd" unitRef="CHF" decimals="-9">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
  <nvs:StockRepurchaseProgramAuthorizedAmount1 contextRef="AR_I-CurrentYearEnd-1" unitRef="CHF" decimals="-9">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
  <nvs:StockRepurchaseProgramAuthorizedAmount1 contextRef="AR_I-CurrentYearEnd-2" unitRef="CHF" decimals="-9">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
  <nvs:WrittenCallOptionsHeldByMarketMaker contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="-6">13000000</nvs:WrittenCallOptionsHeldByMarketMaker>
  <nvs:WrittenCallOptionsHeldByMarketMaker contextRef="AR_I-CurrentYearEnd-2" unitRef="Pure" decimals="-6">11000000</nvs:WrittenCallOptionsHeldByMarketMaker>
  <nvs:WrittenCallOptionsWeightedAverageExercisePrice contextRef="AR_I-CurrentYearEnd-1" unitRef="USDPerShares" decimals="2">63.90</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
  <nvs:WrittenCallOptionsWeightedAverageExercisePrice contextRef="AR_I-CurrentYearEnd-2" unitRef="USDPerShares" decimals="2">62.70</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
  <nvs:WrittenCallOptionsContractualLive contextRef="AR_I-CurrentYearEnd" unitRef="Year" decimals="0">10</nvs:WrittenCallOptionsContractualLive>
  <nvs:WrittenCallOptionsContractualLiveRemaining contextRef="AR_I-CurrentYearEnd" unitRef="Year" decimals="0">3</nvs:WrittenCallOptionsContractualLiveRemaining>
  <nvs:WrittenCallOptionsContractualLiveRemaining contextRef="AR_I-CurrentYearEnd-1" unitRef="Year" decimals="0">4</nvs:WrittenCallOptionsContractualLiveRemaining>
  <nvs:WrittenCallOptionsContractualLiveRemaining contextRef="AR_I-CurrentYearEnd-2" unitRef="Year" decimals="0">5</nvs:WrittenCallOptionsContractualLiveRemaining>
  <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">2500000000</nvs:MaximalAmountOfShareBuybackProgramm>
  <nvs:TaxOnTransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">36000000</nvs:TaxOnTransactionCostsRecordedInEquity>
  <nvs:TaxOnTransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">20000000</nvs:TaxOnTransactionCostsRecordedInEquity>
  <nvs:AmountRecordedInEquityRelatedToHyperinflation contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">22000000</nvs:AmountRecordedInEquityRelatedToHyperinflation>
  <nvs:AmountRecordedInEquityRelatedToHyperinflation contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">38000000</nvs:AmountRecordedInEquityRelatedToHyperinflation>
  <nvs:DividendsPayableAmountPerShare contextRef="AR_I-CurrentYearEnd-1" unitRef="CHFPerShares" decimals="2">2.85</nvs:DividendsPayableAmountPerShare>
  <nvs:DividendsPayableAmountPerShare contextRef="AR_I-CurrentYearEnd-2" unitRef="CHFPerShares" decimals="2">2.80</nvs:DividendsPayableAmountPerShare>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5351000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1859000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">160000000</nvs:OtherSharePurchasesValue>
  <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">114000000</nvs:OtherSharePurchasesValue>
  <nvs:SharepurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-62000000</nvs:SharepurchaseOfTreasuryShares>
  <nvs:SharepurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-24500000</nvs:SharepurchaseOfTreasuryShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">900000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:NumberOfOtherShareSales contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">3000000</nvs:NumberOfOtherShareSales>
  <nvs:OtherShareSalesEquityImpact contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">263000000</nvs:OtherShareSalesEquityImpact>
  <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1490000000</nvs:EquityImpactOfTreasuryShareMovements>
  <nvs:TreasurySharesMovement contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-46200000</nvs:TreasurySharesMovement>
  <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4450000000</nvs:EquityImpactOfTreasuryShareMovements>
  <nvs:TreasurySharesMovement contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-6300000</nvs:TreasurySharesMovement>
  <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">520000000</nvs:EquityImpactOfTreasuryShareMovements>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-23300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-1200000</nvs:OtherSharePurchases>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">5500000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">7800000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">11000000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">9400000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">7400000</nvs:EquityBasedCompensationShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-8200000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-46200000</nvs:ShareMovements>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">78692000000</ifrs-full:Equity>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">31000000</nvs:TreasurySharesMovementOfPeriod>
  <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-11000000</nvs:TreasurySharesMovementOfPeriod>
  <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">27000000</nvs:TreasurySharesMovementOfPeriod>
  <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.039</nvs:WeightedAverageInterestRateLeaseLiabilities>
  <nvs:LeaseIncentives contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">33000000</nvs:LeaseIncentives>
  <nvs:MostMaterialLeaseWithLeaseTermExtension contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-8">600000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">537000000</ifrs-full:AdditionsToRightofuseAssets>
  <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">98000000</nvs:LeaseContractTerminationsRightofuseAssets>
  <nvs:DisposalsAndRetirementsRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">17000000</nvs:DisposalsAndRetirementsRightofuseAssets>
  <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearStart-1" unitRef="USD" decimals="-6">1554000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">305000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">346000000</ifrs-full:AdditionsToRightofuseAssets>
  <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">63000000</nvs:LeaseContractTerminationsRightofuseAssets>
  <nvs:DisposalsAndRetirementsRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">32000000</nvs:DisposalsAndRetirementsRightofuseAssets>
  <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">46000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">33000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">-792000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:DividendsPayableAmountPerShare contextRef="AR_I-CurrentYearEnd" unitRef="CHFPerShares" decimals="2">2.95</nvs:DividendsPayableAmountPerShare>
  <nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-511000000</nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">28298000000</ifrs-full:BondsIssued>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">306000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1949000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">250000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <nvs:AmountRecordedInEquityRelatedToHyperinflation contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">18000000</nvs:AmountRecordedInEquityRelatedToHyperinflation>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2897000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">159000000</nvs:OtherSharePurchasesValue>
  <nvs:SharepurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-34300000</nvs:SharepurchaseOfTreasuryShares>
  <nvs:TreasurySharesMovement contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-8200000</nvs:TreasurySharesMovement>
  <nvs:WrittenCallOptionsHeldByMarketMaker contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="-6">1000000</nvs:WrittenCallOptionsHeldByMarketMaker>
  <nvs:WrittenCallOptionsWeightedAverageExercisePrice contextRef="AR_I-CurrentYearEnd" unitRef="USDPerShares" decimals="2">60.09</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">26000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">196000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8600000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">218000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">476000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <nvs:FinancialAndOtherAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">49000000</nvs:FinancialAndOtherAssets>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">84000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">109000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">76000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1977000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">32000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <nvs:TradePayablesAndOtherLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">144000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:AcquiredCashAndCashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">76000000</nvs:AcquiredCashAndCashEquivalents>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2580000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">379000000</ifrs-full:CashOutflowForLeases>
  <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">56000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
  <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.034</nvs:WeightedAverageInterestRateLeaseLiabilities>
  <nvs:LeaseIncentives contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">0</nvs:LeaseIncentives>
  <nvs:MostMaterialLeaseWithLeaseTermExtension contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">600000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1505000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">55000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">-27000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">89000000</nvs:RepurchaseOfOptions>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:RightOfUseAssetsAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">32000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
  <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">44000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
  <ifrs-full:GrossLeaseLiabilities contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">3612000000</ifrs-full:GrossLeaseLiabilities>
  <nvs:NewLeaseArrangements contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-65000000</nvs:NewLeaseArrangements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearStart-1" unitRef="USD" decimals="-6">1736000000</ifrs-full:LeaseLiabilities>
  <nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-2" unitRef="Pure" decimals="2">0.22</nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-2" unitRef="Pure" decimals="2">0.08</nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">32000000</nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
  <nvs:UndiscountedFutureLeasePayments contextRef="AR_D-CurrentYearStart-1" unitRef="USD" decimals="-6">3283000000</nvs:UndiscountedFutureLeasePayments>
  <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-9">5000000000</nvs:MaximalAmountOfShareBuybackProgramm>
  <nvs:NumberOfOptionsRepurchased contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="-5">-3700000</nvs:NumberOfOptionsRepurchased>
  <nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">181000000</nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears>
  <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">210000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears>
  <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">338000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears>
  <nvs:NoncurrentFinancialAssetsEquityInvestments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1577000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
  <nvs:NoncurrentFinancialAsstetsDebtSecurities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">36000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
  <nvs:NoncurrentFinancialAssetsFundInvestments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">366000000</nvs:NoncurrentFinancialAssetsFundInvestments>
  <nvs:LongTermReceivablesFromFinanceSubleases contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">83000000</nvs:LongTermReceivablesFromFinanceSubleases>
  <ifrs-full:OtherNoncurrentReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">125000000</ifrs-full:OtherNoncurrentReceivables>
  <nvs:ContingentConsiderationReceivable contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">625000000</nvs:ContingentConsiderationReceivable>
  <ifrs-full:NoncurrentLoansAndReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">89000000</ifrs-full:NoncurrentLoansAndReceivables>
  <nvs:MarketableSecurities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">26000000</nvs:MarketableSecurities>
  <nvs:Commodities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">111000000</nvs:Commodities>
  <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1609000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
  <ifrs-full:DerivativeFinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">159000000</ifrs-full:DerivativeFinancialAssets>
  <ifrs-full:Cash contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3750000000</ifrs-full:Cash>
  <ifrs-full:CashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">5908000000</ifrs-full:CashEquivalents>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1863000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">31000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1018000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-17000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3507000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">338000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
  <nvs:NoncurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3169000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">4000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">7000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
  <nvs:LiabilitiesToBanksAndOtherInstitutions contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">233000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
  <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2272000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
  <nvs:InterestBearningAccountsOfAssociatesPayableOnDemand contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2085000000</nvs:InterestBearningAccountsOfAssociatesPayableOnDemand>
  <ifrs-full:ShorttermBorrowings contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">976000000</ifrs-full:ShorttermBorrowings>
  <ifrs-full:CommercialPapersIssued contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">4258000000</ifrs-full:CommercialPapersIssued>
  <ifrs-full:DerivativeFinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">194000000</ifrs-full:DerivativeFinancialLiabilities>
  <ifrs-full:WeightedAverageShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-6">2277000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-6">19000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <nvs:CommitmentForRepurchaseOwnShares contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1769000000</nvs:CommitmentForRepurchaseOwnShares>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">587000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">199000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">62000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">197000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:UncalledCapitalCommitmentsForInvestmentsInFunds contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">87000000</nvs:UncalledCapitalCommitmentsForInvestmentsInFunds>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">206000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <nvs:UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">201000000</nvs:UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
  <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">101000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
  <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear" unitRef="CHF" decimals="-6">90000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1921000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">293000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-39000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1501000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8344000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7552000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">130000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
  <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">702000000</ifrs-full:InventoryWritedown2011>
  <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">255000000</ifrs-full:ReversalOfInventoryWritedown>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">74000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.003</nvs:AverageInterestRateOnLoansReceived>
  <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.79</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
  <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.020</nvs:AverageInterestRateOnBorrowings>
  <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.050</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">9000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">14000000</nvs:ValueOfTaxLossCarryforwardsExpired>
  <nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">4500000000</nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">7000000000</nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3296000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-9">27000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
  <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-9">26000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
  <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">7700000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
  <nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">0</nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets>
  <nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">0</nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets>
  <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">14</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
  <nvs:BorrowingsCreditFacilityShortTerm contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-9">7000000000</nvs:BorrowingsCreditFacilityShortTerm>
  <dei:EntityCommonStockSharesOutstanding contextRef="AR_I-CurrentYearEnd" unitRef="Shares" decimals="0">2256822048</dei:EntityCommonStockSharesOutstanding>
  <nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.020</nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">-430000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">1168000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">137000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.136</ifrs-full:ApplicableTaxRate>
  <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.046</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.003</ifrs-full:TaxRateEffectOfTaxLosses>
  <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.003</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
  <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.007</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
  <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
  <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.002</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
  <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.003</ifrs-full:TaxRateEffectFromChangeInTaxRate>
  <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.002</nvs:EffectOfWriteoffOfDeferredTaxAssets>
  <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.008</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
  <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.023</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
  <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.019</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">29000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">9786000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">92000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">932000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">501000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">21000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">7000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">18248000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1687000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">30000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-2000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-1000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1471000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">268000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">521000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">31000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">11403000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">6948000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">12417000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">7142000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">12797000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">107000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">220000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">89000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">645000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">53000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">220000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">395000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">32000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">94000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">918000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">239000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">60000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">592000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">249000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">107000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-113000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1075000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">285000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">122000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2214000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">366000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">714000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">761000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">64000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">98000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">165000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">39000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">98000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">217000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">20000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">229000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">153000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">18000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">182000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">67000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">180000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">958000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1067000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">239000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">912000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">952000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">282000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">283000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">124000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">110000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">273000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">247000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">41000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">41000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">16000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">17000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">3080000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2509000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">370000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">315000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">12000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">12000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">324000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">100000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">116000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">101000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">768000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">632000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">141000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">506000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">422000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">443000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">13660000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">-447000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">-428000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">2100000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">2147000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1603000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">93000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">988000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">120000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">8097000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">11887000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">843000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">2208000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">9878000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">8940000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">14095000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">1186000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">615000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">961000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-293000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-354000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-308000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1793000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1295000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.117</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.143</ifrs-full:ApplicableTaxRate>
  <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.048</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.017</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</ifrs-full:TaxRateEffectOfTaxLosses>
  <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</ifrs-full:TaxRateEffectOfTaxLosses>
  <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.007</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
  <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.004</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
  <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.000</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
  <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.037</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
  <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
  <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
  <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.005</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
  <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.002</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
  <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.014</ifrs-full:TaxRateEffectFromChangeInTaxRate>
  <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</ifrs-full:TaxRateEffectFromChangeInTaxRate>
  <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.040</nvs:EffectOfWriteoffOfDeferredTaxAssets>
  <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.002</nvs:EffectOfWriteoffOfDeferredTaxAssets>
  <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.006</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
  <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.000</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
  <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.022</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
  <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.005</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
  <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.030</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.003</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.183</ifrs-full:AverageEffectiveTaxRate>
  <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.201</ifrs-full:AverageEffectiveTaxRate>
  <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.092</ifrs-full:AverageEffectiveTaxRate>
  <nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.037</nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain>
  <nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.026</nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.004</nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">11000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">19000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">40000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-858000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-82000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-1403000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">123000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">248000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">39000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">217000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">164000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">79000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2858000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">269000000</ifrs-full:RightofuseAssets>
  <ifrs-full:Goodwill contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">8906000000</ifrs-full:Goodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">11121000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">732000000</ifrs-full:DeferredTaxAssets>
  <nvs:FinancialAndOtherNoncurrentAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">526000000</nvs:FinancialAndOtherNoncurrentAssets>
  <ifrs-full:Inventories contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1469000000</ifrs-full:Inventories>
  <nvs:TradeReceivablesAndOtherCurrentAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1787000000</nvs:TradeReceivablesAndOtherCurrentAssets>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">628000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1713000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">269000000</ifrs-full:LeaseLiabilities>
  <nvs:CurrentAndNoncurrentFinancialDebt contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3538000000</nvs:CurrentAndNoncurrentFinancialDebt>
  <nvs:TradePayablesProvisionsAndOtherLiabilities contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2751000000</nvs:TradePayablesProvisionsAndOtherLiabilities>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">113000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">36000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <nvs:NetAssetsDerecognized contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-20025000000</nvs:NetAssetsDerecognized>
  <ifrs-full:DividendsPayable contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">23434000000</ifrs-full:DividendsPayable>
  <ifrs-full:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed>
  <nvs:DistributionOfDividendToDividendBearingShares contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1273000000</nvs:DistributionOfDividendToDividendBearingShares>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">123000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:TransactionCosts contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">114000000</nvs:TransactionCosts>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1777000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">32000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1809000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">860000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">949000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">638000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">142000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">15000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">113000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">71000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">58000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-101000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">42000000</ifrs-full:DepreciationAndAmortisationExpense>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-29000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <nvs:DivestedCashAndCashEquivalents contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">628000000</nvs:DivestedCashAndCashEquivalents>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-39000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-657000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-502000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-1001000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <nvs:ProceedsFromCurrentAndNoncurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3492000000</nvs:ProceedsFromCurrentAndNoncurrentBorrowings>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">212000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">57000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">174000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-424000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-40000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">0</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-238000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-345000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">33000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">104000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-47000000</nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations>
  <nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-246000000</nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations>
  <nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-40000000</nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-186000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <nvs:RepaymentOfIntercompanyBalances contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">3100000000</nvs:RepaymentOfIntercompanyBalances>
  <ifrs-full:Borrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">3500000000</ifrs-full:Borrowings>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-Transaction-Alcon-4-April-9_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">1300000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:DividendsPayable contextRef="AR_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">26400000000</ifrs-full:DividendsPayable>
  <ifrs-full:NetAssetsLiabilities contextRef="AR_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NetAssetsLiabilities>
  <ifrs-full:OtherBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">3200000000</ifrs-full:OtherBorrowings>
  <ifrs-full:OtherBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsUSDMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">2800000000</ifrs-full:OtherBorrowings>
  <ifrs-full:OtherBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsEURMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">400000000</ifrs-full:OtherBorrowings>
  <nvs:AdditionalBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">300000000</nvs:AdditionalBorrowings>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">0</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4577000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-207000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-28000000</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-166000000</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-194000000</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">7149000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">7153000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3983000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3170000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2754000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">585000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">61000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">126000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-234000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">25000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-260000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-74000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-186000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-186000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:RevenueFromInterest>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">235000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1052000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">391000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">13000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">93000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:AdditionsToRightofuseAssets>
  <nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-662000000</nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-89000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">246000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-385000000</nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:DepreciationAndAmortisationExpense>
  <nvs:ProceedsFromCurrentAndNoncurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">0</nvs:ProceedsFromCurrentAndNoncurrentBorrowings>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-19000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">163000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">-28000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">286000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">276000000</ifrs-full:RightofuseAssets>
  <nvs:GrossLeaseLiabilitiesDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">222000000</nvs:GrossLeaseLiabilitiesDiscontinuedOperations>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">54000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-39000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-88000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">88000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">89000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">75000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">424000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">289000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">135000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">418000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">505000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">93000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">6000000</nvs:OtherNetAssets>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">173000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">71000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">21000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">322000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">303000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">86000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">16000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">187000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">195000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">81000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">385000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">303000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">659000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">515000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">261000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">912000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">20000000</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-117000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-58000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">3000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">2000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">19000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">433000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">115000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">11463000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">3000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-6328000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-562000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1170000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">447000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">51000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-33000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-5124000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">6339000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">14135000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1615000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">24000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">332000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">112000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1551000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">465000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">695000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">12377000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">433000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">491000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-373000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-5807000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">6570000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">3975000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-10063000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-731000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">228000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">827000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1543000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">14038000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">956000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1656000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-13000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1774000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">355000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">630000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">9000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">2678000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">2000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">17155000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-9726000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-9000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">110000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">898000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1674000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-1541000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-11924000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">13674000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">3948000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">296000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">595000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">5000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-101000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-168000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">18000000</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">8000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">16807000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">6837000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">9970000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">16396000000</ifrs-full:PlanAssetsAtFairValue>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">800000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">34904000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.39</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">15106000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">6167000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">8939000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">14457000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-411000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-649000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">848000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">795000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">33032000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.43</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1573000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3042000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1366000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">88000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">88000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">25000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">36000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">64000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1615000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1517000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1491000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3434000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1573000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1400000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1819000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">5007000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">4408000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">516000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">466000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">52000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-89000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-88000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">549000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">338000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">449000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1245000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">286000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">246000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">295000000</nvs:LeaseLiabilitiesUndiscounted>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">2002000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">2272000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">2067000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">2631000000</ifrs-full:Borrowings>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">202000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">246000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1198000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">41000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">691000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">229000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">274000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">248000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">160000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">186000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">226000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">325000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1191000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">41000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">163000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">202000000</nvs:LeaseLiabilitiesUndiscounted>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">2583000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">2546000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">2321000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">2142000000</ifrs-full:Borrowings>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">138000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">173000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">483000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1182000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">148000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">183000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">415000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">515000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">129000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">160000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1165000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">281000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">119000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">150000000</nvs:LeaseLiabilitiesUndiscounted>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">2139000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">3302000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">15638000000</ifrs-full:Borrowings>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">383000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">11073000000</ifrs-full:NetDebt>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">-3439000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">11243000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">57000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">110000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">170000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">11243000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">11355000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">15638000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">135000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">15503000000</ifrs-full:NetDebt>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">2419000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">3003000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">1027000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">2326000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">-4251000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">21000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">15638000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">15802000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">1409000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">1081000000</ifrs-full:LeaseLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">345000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">3311000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">3466000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1668000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1384000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">437000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">466000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB" unitRef="USD" decimals="-6">288000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB" unitRef="USD" decimals="-6">341000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY" unitRef="USD" decimals="-6">208000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY" unitRef="USD" decimals="-6">279000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP" unitRef="USD" decimals="-6">191000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP" unitRef="USD" decimals="-6">202000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD" unitRef="USD" decimals="-6">153000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD" unitRef="USD" decimals="-6">125000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL" unitRef="USD" decimals="-6">148000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL" unitRef="USD" decimals="-6">165000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD" unitRef="USD" decimals="-6">125000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD" unitRef="USD" decimals="-6">129000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">124000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">89000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1564000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1655000000</ifrs-full:CurrentTradeReceivables>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-93000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-95000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-190000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-126000000</nvs:ProvisionForDoubtfulReceivable>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8310000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember" unitRef="USD" decimals="-6">7714000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember" unitRef="USD" decimals="-6">7763000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">150000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">161000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">118000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">123000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8396000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8217000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8301000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">59000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">89000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">47000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">13000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">12000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">61000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" unitRef="USD" decimals="-6">102000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" unitRef="USD" decimals="-6">103000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember" unitRef="USD" decimals="-6">77000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember" unitRef="USD" decimals="-6">96000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember" unitRef="USD" decimals="-6">149000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember" unitRef="USD" decimals="-6">150000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">53419000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">57333000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">2384000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">67725000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">35700000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">16167000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember" unitRef="USD" decimals="-6">2980000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">6253000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">35412000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">5960000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">2253000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">69025000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">186000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">342000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">3550000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">22000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">3914000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-9069000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">9069000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">265000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">243000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">259000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">767000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">75000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">544000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">436000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">1055000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-61000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">49000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">254000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">335000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">26825000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">7429000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">884000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">43548000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">1558000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">2580000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">8600000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">196000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">218000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">9014000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-9272000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">9274000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">339000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">674000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">412000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">1425000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">421000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">101000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">39000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">572000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">916000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">208000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">58000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">2568000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">205000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">3039000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">30321000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">6893000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">1115000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">26999000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1350000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">34028000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">61000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">655000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">2042000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">696000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">127000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">10000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">5009000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">122000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">44000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">57000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-1019000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">1474000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">75000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1001000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">9000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">512000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">2201000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">36000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">57000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">1797000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">555000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">110000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">28218000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1248000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">26000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">10000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">7000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-1038000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">1265000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">23000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">847000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">2000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">23000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:AdditionsIncludedInDisposalGroupToTheDateOfReclassification contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">0</nvs:AdditionsIncludedInDisposalGroupToTheDateOfReclassification>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">-332000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-11000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-36000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">12000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-10000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-276000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-1112000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-2000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-1400000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">9000000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">249000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember" unitRef="USD" decimals="-6">2980000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">5369000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">4440000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">5960000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">572000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">19570000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">1000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-4000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-3000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember_srt-2020LitigationCaseAxis_nvs-2020Q4TennesseeClassActionMember" unitRef="USD" decimals="-6">85000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">11126000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2220000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">16484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">14342000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">13789000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">11864000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2142000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2491000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2754000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">16280000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">14618000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">28893000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.37</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">670000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3552000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1205000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">630000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1717000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">15000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">121000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">524000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">658000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2311000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1301000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1241000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">54</nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AmiodaroneMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">5</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember" unitRef="USD" decimals="-8">700000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ReclastAclastaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember" unitRef="Pure" decimals="0">20</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TaxotereMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">3000</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-524000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-454000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">134000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">522000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">9654000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">2210000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">404000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">262000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">194000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">145000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">806000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">817000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">440000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">929000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">581000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">457000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">521000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">556000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">84000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">19000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1736000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">925000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">881000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">691000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">481000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">334000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">86000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">13000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">450000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">332000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">304000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">169000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">250000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">10679000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">3110000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1765000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1674000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">1</nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-8">300000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">39889000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.44</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2516000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1562000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1277000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">833000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">17000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">446000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">454000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">80000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1833000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1290000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2487000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">665000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3788000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">701000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">3216000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">400000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">318000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">138000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">569000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">315000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">124000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">16000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">459000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">187000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">195000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember" unitRef="Pure" decimals="0">80</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfDiscountRatesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-885000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfDiscountRatesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">942000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">589000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-143000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">61000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-61000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.40</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.28</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.27</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.36</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.34</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.60</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">89000000</nvs:RepurchaseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">3331000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">3056000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLoss>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">74168000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">60000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-10279000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">56598000000</ifrs-full:Equity>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-32000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">11403000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-34668000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">55474000000</ifrs-full:Equity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">189000000</nvs:TaxesOnTreasuryShares>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">833000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">18000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">210000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">5511000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">11525000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-207000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">11732000000</ifrs-full:ProfitLoss>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78617000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-7824000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">78614000000</ifrs-full:Equity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-13000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">79000000</nvs:TransactionCostsRecordedInEquity>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">756000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">263000000</nvs:OtherShareSales>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">434000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">1973000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaid>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">12210000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-401000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">74228000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">12611000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">59000000</ifrs-full:Equity>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">21000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">77000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">68000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">59000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-21000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-21000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-5000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-26000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember" unitRef="USD" decimals="-6">330000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed>
  <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NAGAndNovartisPharmaSpAMember" unitRef="USD" decimals="-6">125000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember" unitRef="USD" decimals="-8">1300000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPharmaKKMember" unitRef="JPY" decimals="-6">4000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">2656000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">2575000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">309000000</nvs:SelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">2804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">313000000</nvs:SelectedNoncurrentAssets>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">5651000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">181000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">36000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">625000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1173000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1827000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1111000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">466000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1158000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">33000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1215000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1323000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" unitRef="USD" decimals="-6">61000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" unitRef="USD" decimals="-6">329000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember" unitRef="USD" decimals="-6">21839000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8301000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember" unitRef="USD" decimals="-6">2036000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember" unitRef="USD" decimals="-6">20744000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember" unitRef="USD" decimals="-6">963000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" unitRef="USD" decimals="-6">297000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" unitRef="USD" decimals="-6">1609000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8217000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">9658000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">11112000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember" unitRef="USD" decimals="-6">5424000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember" unitRef="USD" decimals="-6">32623000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">719000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">2289000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">22167000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">188000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">1836000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommitmentForRepurchaseOfOwnSharesMember" unitRef="USD" decimals="-6">1769000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">2085000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">4258000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">28298000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember" unitRef="USD" decimals="-6">5403000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember" unitRef="USD" decimals="-6">2005000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember" unitRef="USD" decimals="-6">43022000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">2005000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember" unitRef="USD" decimals="-6">1949000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1949000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember" unitRef="USD" decimals="-6">1263000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1069000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1065000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">159000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1613000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1263000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1069000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">625000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1153000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1451000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">2604000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1046000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">23000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">61000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">126000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">163000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">581000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1557000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1213000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">2189000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1036000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1036000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">29000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">29000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1065000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">159000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1153000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">460000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">625000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1046000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">23000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">622000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">191000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">431000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">74000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">10000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">282000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">390000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">108000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">430000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">189000000</nvs:GrossDeferredTaxAssets>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">53000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">89000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">241000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3918000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">110000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1945000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">-58000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1351000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">5269000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1469000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3610000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2141000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">45000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">-39000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">605000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">8000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">4151000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1233000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">5384000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:AmortizationPriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">102000000</nvs:AmortizationPriorToClassificationToAssetsHeldForSale>
  <nvs:AmortizationPriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">73000000</nvs:AmortizationPriorToClassificationToAssetsHeldForSale>
  <nvs:AmortizationPriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">29000000</nvs:AmortizationPriorToClassificationToAssetsHeldForSale>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">169000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">475000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">2000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">181000000</ifrs-full:Inventories>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">3000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">841000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">2000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">4000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">25000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">31000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">37000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">220000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">13000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">4195000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">8558000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">38000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">4195000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">93000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">930000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">904000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">20000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">-4321000000</ifrs-full:NetDebt>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">4288000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">8609000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">9712000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">9746000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">14000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">4243000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">4243000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">130000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">807000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">814000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">4373000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">-5373000000</ifrs-full:NetDebt>
  <nvs:CommitmentForRepurchaseOwnShares contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">1769000000</nvs:CommitmentForRepurchaseOwnShares>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-103000000</ifrs-full:NetDebt>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">1402000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">29000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4624000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4656000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">1373000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">1373000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">79000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">1505000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">1400000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">2781000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">2302000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-479000000</ifrs-full:NetDebt>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">26000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-36000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">65000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">5222000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">62000000</nvs:ContingentConsiderationLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4114000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4096000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">84000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">2219000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">77000000</ifrs-full:LeaseLiabilities>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-82000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">5239000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">110000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">2218000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">1100000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">1571000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">24000000</nvs:ContingentConsiderationLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">639000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">10621000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">10661000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">-1846000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">692000000</ifrs-full:LeaseLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">5000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">622000000</ifrs-full:LeaseLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">582000000</nvs:ContingentConsiderationLiabilities>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">-1531000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">9104000000</ifrs-full:NetDebt>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">10621000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">10612000000</ifrs-full:NetDebt>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">9000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">9150000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">9110000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">6000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">9110000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">143000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">348000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">36000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">233000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">329000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">78000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">225000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">568000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2616800000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2467000000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2527300000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2550600000</ifrs-full:NumberOfSharesIssued>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-23300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-66200000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-60300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-66200000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-23300000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-60300000</nvs:ShareMovements>
  <nvs:TreasurySharesWithRestrictedUse contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">103000000</nvs:TreasurySharesWithRestrictedUse>
  <nvs:TreasurySharesWithRestrictedUse contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">117600000</nvs:TreasurySharesWithRestrictedUse>
  <nvs:TreasurySharesWithRestrictedUse contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">121600000</nvs:TreasurySharesWithRestrictedUse>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">52100000</nvs:ShareMovements>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">7400000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">9400000</nvs:EquityBasedCompensationShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">7800000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">5500000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-1200000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-22900000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">59900000</nvs:ShareMovements>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">60300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">66200000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">23300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-23300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-60300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-239400000</nvs:NumberOfTreasuryShares>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-262300000</nvs:NumberOfTreasuryShares>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-210200000</nvs:NumberOfTreasuryShares>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-299300000</nvs:NumberOfTreasuryShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">900000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:NumberOfOtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">3000000</nvs:NumberOfOtherShareSales>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">11000000</nvs:EquityBasedCompensationShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="VEF" decimals="-5">1400000</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">50</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">450750</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.40</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="VND" decimals="-9">70000000000</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ILS" decimals="0">1000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-5">2200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PHP" decimals="-5">298800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PHP" decimals="-5">30000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">22600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.060</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">7700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">6000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.40</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CAD" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">10100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="1">155.5</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">25000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">50000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">3</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">9300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">5000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">160000000</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TWD" decimals="-5">170000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="THB" decimals="-5">302000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">98000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">6700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">265000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">50000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="UAH" decimals="-5">8000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AED" decimals="-5">7000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">25500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">5400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">250000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="0">3904</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">72200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">650</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PKR" decimals="-8">6700000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">10000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PEN" decimals="-5">6100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PLN" decimals="-5">44200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PLN" decimals="-5">25600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PLN" decimals="-5">11400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">499900</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RON" decimals="-5">3000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RON" decimals="-5">105200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RUB" decimals="-5">20000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RUB" decimals="-5">500000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RUB" decimals="-5">57400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SAR" decimals="-5">30000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SGD" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SGD" decimals="-5">45000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SGD" decimals="-5">39000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">48400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ZAR" decimals="-5">86300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ZAR" decimals="-5">3000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="KRW" decimals="-8">24500000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9855</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9855</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">63000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">270450</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">9300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">6000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SEK" decimals="-5">5000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">10000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">100200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">50000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">350000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">20000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">18900000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">251000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">5000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="DZD" decimals="-5">650000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ARS" decimals="-5">906100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AUD" decimals="0">2</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AUD" decimals="-5">3800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AUD" decimals="-5">11600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">32700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="BDT" decimals="-5">162500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.60</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.60</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">7100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">19200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">110600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">12000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">30000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">20000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">370000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="BRL" decimals="-5">265000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="BRL" decimals="-5">190000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CAD" decimals="-5">1200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CAD" decimals="-5">80800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CLP" decimals="-8">2000000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">30000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HKD" decimals="0">200</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">320000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">12000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">3200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">57600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="COP" decimals="-8">7900000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HRK" decimals="-5">25600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CZK" decimals="-5">51500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CZK" decimals="-5">44700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="DKK" decimals="-5">14000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="DKK" decimals="-5">12000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">4000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EGP" decimals="-5">193800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9977</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9977</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EGP" decimals="0">250000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">459000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">903000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">43400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">76734</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">4200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">5400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">25000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">25600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">26000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">93700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">42100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">26000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">233900000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HUF" decimals="-5">545600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HUF" decimals="-5">883000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="INR" decimals="-5">123500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.7068</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.7068</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="INR" decimals="-5">60000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="INR" decimals="-5">32000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="IDR" decimals="-8">7700000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">25000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">18200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">119000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-8">6000000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-5">8500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-5">100000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">3000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">100000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MYR" decimals="-5">3300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MXN" decimals="-5">205000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MXN" decimals="-5">468200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MAD" decimals="-5">80000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">4500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">18000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">907560</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="NZD" decimals="0">820000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="NOK" decimals="-5">1500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">395000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4361000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">74227000000</ifrs-full:Equity>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-5064000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">329000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4340000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-100000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">77639000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4340000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">969000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">-177000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">237000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">60000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-56000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLoss>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-32000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">3038000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">798000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">724000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">89000000</nvs:RepurchaseOfOptions>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-13000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-7814000000</ifrs-full:ChangesInEquity>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">752000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">79000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaid>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">12129000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-482000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">12611000000</ifrs-full:ProfitLoss>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">1960000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">430000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:ReductionOfIssuedCapital>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">261000000</nvs:OtherShareSales>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">82191000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">82194000000</ifrs-full:Equity>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">11732000000</ifrs-full:ProfitLoss>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">11638000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-94000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">189000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">207000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">5480000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">828000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">18000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-10134000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">57157000000</ifrs-full:Equity>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8016000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">59275000000</ifrs-full:Equity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-34557000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">77876000000</ifrs-full:Equity>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">69400000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">63900000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">67500000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">40600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">42500000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">2600000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">20700000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">22500000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">25600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">41100000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">0.59</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">35000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">1.55</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.71</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">1.76</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.96</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="3">0.015</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">190000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TabrectaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">35000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="3">0.065</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
  <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.065</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">442000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KesimptaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.015</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">1.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">1.64</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">320000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">116000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1070000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">192000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">1911000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">452000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">393000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">360000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">361000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">170000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">26000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">164000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">8000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">51000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">623000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">630000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">703000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">26000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">841000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1487000000</ifrs-full:RightofuseAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">468000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">2932000000</nvs:NetOperatingAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">145000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">145000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">24481000000</ifrs-full:NetDebt>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">15938000000</ifrs-full:NetDebt>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">227000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1122000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">42000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1543000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">0</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">0</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">0</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">136000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">54000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">454000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">49000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">34000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">21718000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">4548000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29645000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">925000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">35121000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">8274000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">152000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">592000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">249000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">506000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1880000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1585000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1539000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.30</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1556000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1416000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1338000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1155000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1114000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">977000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">975000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">755000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">828000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">480000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">235000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">167000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">278000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">76000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1189000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1139000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">14711000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">14370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">13428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">6998000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">7268000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="USD" decimals="-6">24302000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="USD" decimals="-6">23344000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="USD" decimals="-6">21464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1050000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.67</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1297000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1064000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1023000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1025000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1002000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">485000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">419000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">417000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">2291000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">2587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">6303000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">2086000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">2046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">2463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">-0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">1995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">4410000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">4776000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">4558000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">3551000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">2837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.30</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">554000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">4868000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">4222000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">3392000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3223000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">103000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">60000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">80000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">4323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3429000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1173000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1039000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">22000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">25000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1825000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1767000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1726000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.45</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1028000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.68</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">24000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">-0.96</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">22000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">2498000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1750000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">670000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">656000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">37714000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9731000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">792000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">783000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">189000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">141000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-981000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-871000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39805000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">38497000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9835000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9872000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-981000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-871000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1018000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1092000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">53000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">63000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">168000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">24000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">10927000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">10050000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5252000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5334000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-1058000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-959000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29896000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29539000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4636000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4601000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">245000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">112000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">11657000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">11617000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2076000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2218000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">464000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">534000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8118000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8152000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">862000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">922000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1586000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">176000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">167000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">644000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">278000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1871000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2069000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">831000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">749000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">488000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">608000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9172000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9287000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1043000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">551000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-63000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-752000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">27384000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">8061000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">9880000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">36044000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">11563000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-11000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">11446000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">8509000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">-24000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">-44000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-7000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">194000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">85000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">52000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">128000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">8000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">9430000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1235000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">8892000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">152000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">83000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">647000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">105000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">68000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">741000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">177000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">34892000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-836000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">35633000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">10036000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-836000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1188000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">62000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">16000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9870000000</ifrs-full:CostOfSales>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">6432000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">7871000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1332000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-800000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5530000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-890000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">26951000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4568000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">70000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">10907000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2305000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">505000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">7675000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">814000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">977000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">505000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">147000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1475000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">622000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">512000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">83112000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">71225000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">16825000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">16468000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">32122000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">30677000000</ifrs-full:Assets>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">15472000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">15332000000</ifrs-full:Liabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1489000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">110000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">143000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">926000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1114000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">229000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">217000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">133000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">54000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">264000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">67000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">15000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">56839000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">46336000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9817000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9863000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">12664000000</nvs:NetOperatingAssets>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9632000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1849000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1888000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">551000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">549000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">67640000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">55893000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">13039000000</nvs:NetOperatingAssets>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">3786000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">3804000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">56135000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">43683000000</ifrs-full:Liabilities>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">76000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">76000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">768000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">669000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">141000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">914000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">1175000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">18750000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">5339000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">21720000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">520000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">27586000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7767000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">85000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">156000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">859000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">25000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1125000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1482000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">301000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1318000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1345000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">440000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">202000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1758000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1547000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1783000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">4376000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3974000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3428000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3462000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2836000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">914000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1138000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">841000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2587000000</ifrs-full:DepreciationAndAmortisationExpense>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">4120000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">3972000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">2554000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">4518000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">2607000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">2442000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">4115000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4FHoffmanLaRocheAGAndRocheSpAMember" unitRef="USD" decimals="-6">452000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4FHoffmanLaRocheAGAndRocheSpAMember" unitRef="EUR" decimals="-6">385000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">2442000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">2505000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">3933000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-335000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-38000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">26524000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-406000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-301000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">29999000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-322000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">101000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-925000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">8813000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-1550000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">36809000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-30916000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">3462000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">567000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">914000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-148000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-24632000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">1175000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-30306000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">2836000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">983000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">28787000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">163000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">42000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-4758000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">105000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-721000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">40000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">101000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">72000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-885000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">230000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-46000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-107000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">4184000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">128000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-145000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">1112000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-1272000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">21000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">175000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">6000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-937000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">419000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-1304000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">137000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">621000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">492000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-43000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-8000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-26000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">10000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-20000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">17000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">15000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-19000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">536000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">0</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-4000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1182000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-66000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">10000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">11000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1290000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-60000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">34000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">2000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-7000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-37000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">268000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">87000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">153000000</ifrs-full:OtherProvisions>
  <ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">8000000</ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">492000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">534000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">479000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">145000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">72000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">33000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">459000000</ifrs-full:OtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">438000000</ifrs-full:OtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">507000000</ifrs-full:OtherProvisions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">23000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">969000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-8000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">936000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-23000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">913000000</ifrs-full:Equity>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">25000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-25000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-69000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">31000000</ifrs-full:ChangesInEquity>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-34000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">13000000</ifrs-full:PurchaseOfTreasuryShares>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">2000000</nvs:OtherShareSales>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-100000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-69000000</ifrs-full:Equity>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">31000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">5000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-53000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">27000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-80000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-31000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">8000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">18000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">6000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">537000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">14000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">528000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">963000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">207000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">990000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">129000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">87000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">155000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">100000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">30000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">12000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">21000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">330000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">305000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">330000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">305000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:ImpairmentChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2000000</nvs:ImpairmentChargePriorToClassificationToAssetsHeldForSale>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-18332000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-2118000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2846000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-26000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">3000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">205000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">1345000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-14930000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-43000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2004000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">447000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">1318000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-1108000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-15955000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">485000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">494000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">984000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">2657000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">70000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">-1906000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-21218000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-1120000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">54000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-126000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-2005000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-20969000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">515000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">338000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">3215000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">39000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">421000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-26566000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-2193000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-1267000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-92000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">416000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">400000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">108000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-163000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-816000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-2000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:ImpairmentChargesRelatedToDisposalGroupHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-42000000</nvs:ImpairmentChargesRelatedToDisposalGroupHeldForSale>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">38000000</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">0</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">1906000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">2592000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">3000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">181000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">12818000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">12296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:NumberOfBusinessUnits contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="0">2</nvs:NumberOfBusinessUnits>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">24000000</nvs:OtherRevenueOther>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">128000000</nvs:MilestoneIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">162000000</ifrs-full:RevenueFromRoyalties>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">874000000</nvs:ProfitSharingIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">37000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">55000000</nvs:OtherRevenueOther>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">201000000</nvs:MilestoneIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">107000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">104000000</ifrs-full:RevenueFromRoyalties>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">835000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">732000000</nvs:ProfitSharingIncome>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9141000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8634000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8458000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8097000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2469000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2649000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29643000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">28573000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">26258000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">18790000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">29916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">9097000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">24671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1331000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3551000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1479000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">905000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1220000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">5736000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">7946000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">23028000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">23925000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">17292000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">26946000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">517000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">319000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">292000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">554000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">828000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">424000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">983000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1002000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">977000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">977000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1023000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">939000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1039000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">472000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1028000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">578000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1039000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">698000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1155000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">593000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">627000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1556000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1121000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1068000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1576000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1163000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">28646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">5958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">9068000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">17967000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">480000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">230000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">316000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">485000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">367000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">975000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">755000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">525000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1012000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1025000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1064000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">978000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1297000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">929000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1173000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1173000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1114000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1114000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">857000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1338000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1297000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1539000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">725000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1416000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">704000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1585000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1726000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">801000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2086000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1076000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1880000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1487000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3223000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2086000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">5881000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">515000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">369000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">473000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">461000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">964000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">879000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">602000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">973000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="1">85.0</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">9600000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">9600000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">7100000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">1400000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">2500000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.09</nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">33000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <ifrs-full:GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination contextRef="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">14000000</ifrs-full:GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">361000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PercentageOfVotingEquityInterestsAcquired contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.91</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">285000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">76000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">355000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3400000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">1900000000</nvs:PotentialMilestoneMaximumPayments>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">100000000</nvs:CustomaryPurchasePriceAdjustment>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3700000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3500000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">200000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3600000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3600000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">100000000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:RevenueOfAcquiree contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">200000000</ifrs-full:RevenueOfAcquiree>
  <nvs:RevenueOfAcquireeFullYear contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">300000000</nvs:RevenueOfAcquireeFullYear>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">13484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5115000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4963000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-6">300000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">336000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-6">100000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">112000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">196000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">26000000</nvs:OtherNetAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">16000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">86000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">77000000</nvs:PotentialMilestoneMaximumPayments>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">294000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">324000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">247000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">273000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">47000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">51000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">238000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">274000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">303000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">27000000</nvs:CustomaryPurchasePriceAdjustment>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">30000000</nvs:CustomaryPurchasePriceAdjustment>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">70000000</nvs:PotentialMilestoneMaximumPayments>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="USD" decimals="-6">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="USD" decimals="-6">7244000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="USD" decimals="-6">1928000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">38000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">102000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">42000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">694000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">784000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">826000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="USD" decimals="-6">1607000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="USD" decimals="-6">1436000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="USD" decimals="-6">534000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="USD" decimals="-6">543000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="USD" decimals="-6">7590000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="USD" decimals="-6">7880000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:DivestmentDateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-8">800000000</nvs:DivestmentDateFairValueOfTotalConsiderationTransferred>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1501000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1363000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">772000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">784000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">779000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">0</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">25000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">19000000</ifrs-full:RevenueFromRoyalties>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">11000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">30000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">17000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">12000000</nvs:OtherRevenueOther>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">3000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">10000000</ifrs-full:RevenueFromRoyalties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7089000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7111000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7233000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2557000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2620000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">45000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4000000</nvs:OtherRevenueOther>
  <nvs:NumberOfFranchises contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">3</nvs:NumberOfFranchises>
  <ifrs-full:IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-9">3000000000</ifrs-full:IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners>
  <nvs:PercentageOfEquityInterestSharesReceived contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="Pure" decimals="3">0.047</nvs:PercentageOfEquityInterestSharesReceived>
  <ifrs-full:CurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">31300000000</ifrs-full:CurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">56400000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">24100000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:CurrentAssets contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">27700000000</ifrs-full:CurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">55700000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">22500000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:Revenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">63800000000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">12300000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">-900000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">11400000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:Revenue contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">30400000000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">7200000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">-700000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">6500000000</ifrs-full:ComprehensiveIncome>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-64000000</nvs:PriorYearAdjustment>
  <nvs:ShareOfEstimatedNetAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">2585000000</nvs:ShareOfEstimatedNetAssets>
  <ifrs-full:RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">117000000</ifrs-full:RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">3233000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">913000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-172000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">18800000000</ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">26000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <nvs:CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">5935000000</nvs:CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill>
  <nvs:AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">3472000000</nvs:AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">910000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">799000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-129000000</nvs:PriorYearAdjustment>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-125000000</nvs:PriorYearAdjustment>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-162000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-148000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <nvs:PartialReleaseOfDeferredTaxLiabilityRecognized contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">43000000</nvs:PartialReleaseOfDeferredTaxLiabilityRecognized>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">24000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">40000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <ifrs-full:ProportionOfVotingPowerHeldInAssociate contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
  <ifrs-full:ProportionOfVotingPowerHeldInAssociate contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
  <ifrs-full:ProportionOfVotingPowerHeldInAssociate contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
  <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
  <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
  <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
  <ifrs-full:DividendsReceived contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">487000000</ifrs-full:DividendsReceived>
  <ifrs-full:DividendsReceived contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">460000000</ifrs-full:DividendsReceived>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">P20Y0M0D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">16900000000</ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">9407000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">8445000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">677000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">662000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">526000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-94000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">75000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">621000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">568000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">601000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">5910000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">-557000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">5353000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">1000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">119000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">4000000</nvs:PriorYearAdjustment>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">-3000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">5790000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-4000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-4000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">225000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">199000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">137000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">33000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">169000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
  <nvs:EmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Shares" decimals="-5">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
  <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-8">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
  <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P15Y4M25D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
  <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">404000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.05</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.00</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.00</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P24Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">13418000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1318000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">9075000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1217000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.006</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.003</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.027</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.001</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P22Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3109000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">222000000</nvs:DefinedBenefitPlanInterestCost>
  <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-102000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1166000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">28000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-159000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1810000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
  <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">186000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-9000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-166000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1620000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
  <nvs:DefinedBenefitPlanSettlementsPlanAssets contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-15000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-2000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1>
  <nvs:InterestIncomeOnLimitationOfFundSurplus contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">202000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">24000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.17</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.17</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">186000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1264000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">372000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">464000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <nvs:ChangeInLimitationOnRecognitionOfFundSurplus contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-16000000</nvs:ChangeInLimitationOnRecognitionOfFundSurplus>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.13</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.15</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.08</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.05</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">1.00</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">1.00</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:EmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Shares" decimals="-5">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
  <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-8">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
  <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P15Y2M13D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">23066000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">22179000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">58000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">77000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-117000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">25000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanSettlementsPlanAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">193000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-39000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">22317000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3285000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3256000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:LimitationOnRecognitionOfFundSurplus contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-65000000</nvs:LimitationOnRecognitionOfFundSurplus>
  <nvs:LimitationOnRecognitionOfFundSurplus contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-68000000</nvs:LimitationOnRecognitionOfFundSurplus>
  <nvs:ChangeInLimitationOnRecognitionOfFundSurplus contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-7000000</nvs:ChangeInLimitationOnRecognitionOfFundSurplus>
  <nvs:InterestIncomeOnLimitationOfFundSurplus contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">4000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
  <nvs:LimitationOnRecognitionOfFundSurplus contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-51000000</nvs:LimitationOnRecognitionOfFundSurplus>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3336000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3321000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-257000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1656000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-304000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">420000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">25602000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">19810000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">18838000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">336000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">330000000</nvs:DefinedBenefitPlanInterestCost>
  <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-168000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
  <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">24000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1791000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">193000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-184000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">283000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1256000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">169000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">49000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.010</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.016</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P24Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P24Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.003</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.004</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.028</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.028</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.003</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
  <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.008</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P22Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P22Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">12147000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2722000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1136000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">8197000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">21000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-126000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">190000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-21000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-11000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">10000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">148000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3538000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3469000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-20000000</nvs:ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">3000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">109000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-35000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P21Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P21Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P23Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P23Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.036</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.044</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">157000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">15000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">30000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">22000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">9000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-76000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">29000000</nvs:DefinedBenefitPlanInterestCost>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">13000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">134000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">119000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">632000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">74000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">10000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-3000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:PlanAssetsAtFairValue>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">2000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">16000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">26000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">954000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">746000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1073000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.065</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.070</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">33000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">574000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-4000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-7000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">132000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">13000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-40000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">20000000</nvs:DefinedBenefitPlanInterestCost>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P21Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">4000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P23Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">510000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">17000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">105000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.063</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.029</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">800000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.3</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">800000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">1400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P0Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P1Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P2Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P1Y4M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.0</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">66.0</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2000000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">89.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">91.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">5600000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">59.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">2200000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">58.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">2600000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">3400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">60.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">2600000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">3400000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">60.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">179000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2600000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">67.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">175000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">339000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">5300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">64.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">60.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">15200000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">5600000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">58.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">6700000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">9600000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">61.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">6700000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">9600000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">61.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">286000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">92.2</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">86.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">3300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">4000000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P0Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P1Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P2Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P1Y6M1D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.0</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">58.3</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">66.1</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">2300000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">2900000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">59.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">16000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">168000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">24000000</ifrs-full:RevenueFromRoyalties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">18885000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">18333000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">8296000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.11</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">19038000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">7837000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.08</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDebtSecuritiesMember" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">13000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-47000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">47000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-36000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">76000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-1448000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">3386000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-116000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-4686000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">352000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-467000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-47000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">13000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" unitRef="USD" decimals="-6">-177000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">315000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-4538000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-4478000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">13000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">62000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-4517000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78695000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">74287000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-4452000000</ifrs-full:Equity>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">5424000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">4700000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">30767000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">22579000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember" unitRef="USD" decimals="-9">3000000000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember" unitRef="USD" decimals="-9">5000000000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember" unitRef="USD" decimals="-9">27000000000</nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised>
  <nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember" unitRef="USD" decimals="-9">24000000000</nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">5000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">683000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">40000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">2291000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">35000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember" unitRef="USD" decimals="-6">3025000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember" unitRef="USD" decimals="-6">2338000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">46000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">2214000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">125000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">127000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">16000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">28000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember" unitRef="USD" decimals="-6">648000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">28000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">14000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember" unitRef="USD" decimals="-6">3780000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">310000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">3400000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">11000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">323000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">23000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">2000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">1000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:TaxLossCarryForwards contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-8">3200000000</nvs:TaxLossCarryForwards>
  <nvs:TaxLossCarryForwards contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-8">1600000000</nvs:TaxLossCarryForwards>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">14000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">28000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">8000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">34000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">62000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">23000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">51000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">164000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">2339000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">5691000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember" unitRef="USD" decimals="-6">967000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember" unitRef="USD" decimals="-6">751000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember" unitRef="USD" decimals="-6">3324000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember" unitRef="USD" decimals="-6">3024000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember" unitRef="USD" decimals="-6">2840000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember" unitRef="USD" decimals="-6">2207000000</ifrs-full:Inventories>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="Pure" decimals="5">0.04400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="Pure" decimals="5">0.99237</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="Pure" decimals="5">0.02400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="USD" decimals="-6">1500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="Pure" decimals="5">0.99225</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="USD" decimals="-6">1495000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="USD" decimals="-6">1497000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="USD" decimals="-6">490000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="Pure" decimals="5">0.03700</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="USD" decimals="-6">500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="Pure" decimals="5">0.98325</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="USD" decimals="-6">489000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="Pure" decimals="5">0.03400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="USD" decimals="-6">2150000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="Pure" decimals="5">0.99287</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="USD" decimals="-6">2139000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="USD" decimals="-6">2142000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="USD" decimals="-6">1826000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="Pure" decimals="5">0.04400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="USD" decimals="-6">1850000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="Pure" decimals="5">0.99196</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="USD" decimals="-6">1825000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="Pure" decimals="5">0.00750</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="EUR" decimals="-6">600000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="Pure" decimals="5">0.99134</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="USD" decimals="-6">670000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="USD" decimals="-6">737000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="USD" decimals="-6">735000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="Pure" decimals="5">0.01625</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="EUR" decimals="-6">600000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="Pure" decimals="5">0.99697</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="USD" decimals="-6">670000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="Pure" decimals="5">0.00250</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="CHF" decimals="-6">500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="Pure" decimals="5">1.00640</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="USD" decimals="-6">517000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="USD" decimals="-6">568000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="USD" decimals="-6">625000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="Pure" decimals="5">0.00625</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="CHF" decimals="-6">550000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="Pure" decimals="5">1.00502</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="USD" decimals="-6">568000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="Pure" decimals="5">0.01050</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="CHF" decimals="-6">325000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="Pure" decimals="5">1.00479</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="USD" decimals="-6">336000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="USD" decimals="-6">369000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="USD" decimals="-6">1737000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="Pure" decimals="5">0.03000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="USD" decimals="-6">1750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="Pure" decimals="5">0.99010</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="USD" decimals="-6">1735000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="Pure" decimals="5">0.04000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="Pure" decimals="5">0.98029</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="USD" decimals="-6">1219000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="USD" decimals="-6">1220000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="USD" decimals="-6">1530000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="Pure" decimals="5">0.00125</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="EUR" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="Pure" decimals="5">0.99127</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="USD" decimals="-6">1392000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="Pure" decimals="5">0.00625</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="EUR" decimals="-6">500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="Pure" decimals="5">0.98480</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="USD" decimals="-6">553000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="USD" decimals="-6">607000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="Pure" decimals="5">0.01800</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="Pure" decimals="5">0.99609</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="Pure" decimals="5">0.02400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="Pure" decimals="5">0.99449</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="USD" decimals="-6">996000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="USD" decimals="-6">998000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="USD" decimals="-6">992000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="Pure" decimals="5">0.03100</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="Pure" decimals="5">0.99109</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="USD" decimals="-6">990000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="Pure" decimals="5">0.00000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="EUR" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="Pure" decimals="5">0.99133</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="USD" decimals="-6">1396000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="USD" decimals="-6">1536000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="USD" decimals="-6">735000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="Pure" decimals="5">0.01125</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="EUR" decimals="-6">600000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="Pure" decimals="5">0.99874</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="USD" decimals="-6">670000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="Pure" decimals="5">0.00500</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="EUR" decimals="-6">750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="Pure" decimals="5">0.99655</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="USD" decimals="-6">837000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="USD" decimals="-6">919000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="USD" decimals="-6">920000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="Pure" decimals="5">0.01375</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="EUR" decimals="-6">750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="Pure" decimals="5">0.99957</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="USD" decimals="-6">838000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="Pure" decimals="5">0.01700</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="EUR" decimals="-6">750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="Pure" decimals="5">0.99217</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="USD" decimals="-6">832000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="USD" decimals="-6">913000000</ifrs-full:BondsIssued>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember" unitRef="USD" decimals="-6">2252000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanSixYearsMember" unitRef="USD" decimals="-6">8991000000</ifrs-full:Borrowings>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">28298000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">22167000000</ifrs-full:BondsIssued>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">233000000</nvs:OtherNoncurrentFinancialDebt>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">188000000</nvs:OtherNoncurrentFinancialDebt>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">28531000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">22355000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">23889000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">31592000000</ifrs-full:Borrowings>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">188000000</nvs:OtherNoncurrentFinancialDebt>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">233000000</nvs:OtherNoncurrentFinancialDebt>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">23701000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">31359000000</ifrs-full:BondsIssued>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:CurrentPortionOfNoncurrentFinancialDebt contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-3190000000</nvs:CurrentPortionOfNoncurrentFinancialDebt>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">22470000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-462000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-27000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">2856000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">23224000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-5000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-2003000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">20353000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">1000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-16000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">93000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-25000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-141000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">26259000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">832000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">392000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">9785000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-129000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">3195000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-1582000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-5000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">7031000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2003000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">48000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">5308000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">366000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">1681000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-2000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-93000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">9678000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CurrentPortionOfNoncurrentFinancialDebt contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">3190000000</nvs:CurrentPortionOfNoncurrentFinancialDebt>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-156000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">1703000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">36000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">221000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">30000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">362000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-33000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">1719000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">12000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">286000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-6000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-20000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">131000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">273000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-51000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-65000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">73000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">8000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-56000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">246000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">156000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4LifeExpectancyMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Increase1YearMember" unitRef="USD" decimals="-6">993000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">62000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-30000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">78.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">86000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">103000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">93.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">4200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">95.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">399000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">349000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">4200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">83.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">213000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">68.9</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">172000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">85.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">0.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">0</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">0.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">0</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">117000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1900000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">67.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">129000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">78.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">13800000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">74.2</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2000000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">75.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1024000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">13300000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">80.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1068000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">151000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">4300000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">76.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">328000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">24800000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">78.9</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1957000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">25800000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">71.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1835000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">25700000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">77.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1981000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4100000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4800000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">9800000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">8700000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">8800000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">5200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">2100000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">2000000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">1300000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">1200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-9">1000000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-6">217000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
  <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-6">101000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
  <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-6">34000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
  <nvs:NumberOfContractsWithRelatedParties contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="Pure" decimals="0">2</nvs:NumberOfContractsWithRelatedParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">1900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember" unitRef="CHF" decimals="0">60000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember" unitRef="CHF" decimals="0">60000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember" unitRef="CHF" decimals="0">60000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrDanielVasellaMember" unitRef="CHF" decimals="0">18228</ifrs-full:KeyManagementPersonnelCompensation>
  <nvs:BorrowingsCreditFacilityUncommitted contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPensionFundMember" unitRef="USD" decimals="-6">500000000</nvs:BorrowingsCreditFacilityUncommitted>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">57000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">18000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">23000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">4000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">24000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">-19000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">39000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">145000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">49000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">15000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">-15000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">3000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">10000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">143000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">366000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">28000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">251000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">12000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">233000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">30000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">12000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">8000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">151000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">31000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">17000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">61000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">109000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">33000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">123000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-163000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">34000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">39000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">6000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">53000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-64000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">581000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-6000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">6000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">488000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">229000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">460000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-5000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">173000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">625000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">-32000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">396000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">35000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">399000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">35000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">173000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">40000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">43000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">-30000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">63000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-123000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-62000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">206000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">90000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-4000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">106000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-1036000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">195000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-907000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">3000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">89000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-401000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-1046000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">116000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-3000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-23000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-5000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">48000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">33000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-10000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-29000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-47000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">3000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-2000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">11000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">25000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">164000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">-468000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">209000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">3179000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">17000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">719000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">710000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">3178000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">38000000</nvs:ContingentConsiderationLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">29000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">3166000000</ifrs-full:NetDebt>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">3195000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">1230000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">1230000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">922000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">952000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">26000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">1256000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">1237000000</ifrs-full:NetDebt>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">16000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">19000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">-428000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">9000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">202000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">181000000</ifrs-full:LeaseLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">122000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">1635000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">110000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">102000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">159000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">9658000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">11112000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">20353000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">6846000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">26259000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">9591000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">9593000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">26463000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">6846000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">20505000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">185000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.141</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.126</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.126</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.104</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.097</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.083</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:BorrowingsCommercialPaperNumberOfPrograms contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4USCommercialPaperProgramsMember" unitRef="Pure" decimals="0">2</nvs:BorrowingsCommercialPaperNumberOfPrograms>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4USCommercialPaperProgramsMember" unitRef="USD" decimals="-9">9000000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember" unitRef="JPY" decimals="-9">150000000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember" unitRef="USD" decimals="-8">1500000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperNumberOfPrograms contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember" unitRef="Pure" decimals="0">1</nvs:BorrowingsCommercialPaperNumberOfPrograms>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">71000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">331000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">382000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">976000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" unitRef="USD" decimals="-6">-101000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:OtherReserves contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" unitRef="USD" decimals="-6">3000000</ifrs-full:OtherReserves>
  <ifrs-full:CurrentLeaseLiabilities contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" unitRef="USD" decimals="-6">268000000</ifrs-full:CurrentLeaseLiabilities>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-466000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">145000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5773000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5064000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-359000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-30000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5919000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-313000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">69000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-466000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5423000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-358000000</nvs:ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">744000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">0</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">129000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">-946000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">1142000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">320000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">354000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">415000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">329000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">4134000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">2992000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">398000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-113000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3387000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1419000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1419000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-149000000</ifrs-full:ChangesInEquity>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4517000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">81000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">354000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">320000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4657000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-92000000</ifrs-full:ChangesInEquity>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4657000000</ifrs-full:Equity>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3387000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">81000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">81000000</ifrs-full:OtherComprehensiveIncome>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-16000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4452000000</ifrs-full:Equity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-113000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-113000000</ifrs-full:ComprehensiveIncome>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3387000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-466000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4452000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" unitRef="USD" decimals="-6">-177000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-47000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">13000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" unitRef="USD" decimals="-6">-177000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">10173000000</nvs:CashFlowFromNetIdentifiableAssets>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="AR_I-CurrentYearEnd_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">7000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">98000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">62000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">4124000000</nvs:CashFlowFromNetIdentifiableAssets>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">13660000000</nvs:CashFlowFromNetIdentifiableAssets>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">33000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">242000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-5000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-2000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-36000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-10006000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-3851000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-13701000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">91000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">18000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">49000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">41000000</ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
  <ifrs-full:ConsiderationPaidReceived contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">95000000</ifrs-full:ConsiderationPaidReceived>
  <nvs:NetCashOutflowsFromDivestments contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">4000000</nvs:NetCashOutflowsFromDivestments>
  <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">196000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
  <nvs:CurrentAssetsDivested contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">96000000</nvs:CurrentAssetsDivested>
  <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">11000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
  <ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">18000000</ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
  <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentAssetsMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember" unitRef="USD" decimals="-6">862000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember" unitRef="USD" decimals="-6">843000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember" unitRef="USD" decimals="-6">315000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember" unitRef="USD" decimals="-6">249000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.17</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.18</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.18</ifrs-full:PercentageOfEntitysRevenue>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.14</nvs:PercentageOfEntitysTradeReceivable>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.14</nvs:PercentageOfEntitysTradeReceivable>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.11</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.13</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.14</ifrs-full:PercentageOfEntitysRevenue>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.12</nvs:PercentageOfEntitysTradeReceivable>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.12</nvs:PercentageOfEntitysTradeReceivable>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.06</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.08</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.08</ifrs-full:PercentageOfEntitysRevenue>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.06</nvs:PercentageOfEntitysTradeReceivable>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.07</nvs:PercentageOfEntitysTradeReceivable>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1590000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">4158000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-90000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">4541000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1883000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5183000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-193000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5474000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1981000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5560000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-107000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5739000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2053000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1769000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">167000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2597000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">7000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2940000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">14000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2272000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1625000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-19000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2467000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-2000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2659000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-1000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1356000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-78000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2182000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">83000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2555000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">109000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1726000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-51000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">12227000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-91000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11956000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-441000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1754000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">9000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11698000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-25000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11868000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-103000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1845000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">67000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11137000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-51000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11094000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-113000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1931000000</ifrs-full:CurrentRefundsProvision>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-110000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-75000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">9000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">6000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">269000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">96000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">10779000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">11000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">70000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">13679000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">2432000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">6376000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">4871000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">9000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">250000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">19000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">11000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">70000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1373000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">7760000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1646000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">151000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-165000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">8000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-29000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">4871000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">2432000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">6457000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1373000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">8019000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1665000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">13760000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">11057000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">159000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">102000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-194000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-185000000</nvs:DerivativeFinancialInstruments>
  <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare contextRef="AR_D-CurrentYear_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember" unitRef="CHFPerShares" decimals="2">3.00</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare>
  <nvs:EstimatedAcquisitionFairValueOfTotalConsideration contextRef="AR_I-CurrentYearEnd_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember" unitRef="USD" decimals="-6">235000000</nvs:EstimatedAcquisitionFairValueOfTotalConsideration>
  <nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_nvs-2020Q4IncomeStatementMember" unitRef="USD" decimals="-6">-234000000</nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset>
  <nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_nvs-2020Q4IncomeStatementMember" unitRef="USD" decimals="-6">-234000000</nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_ifrsfull-2019EquityMember" unitRef="USD" decimals="-6">358000000</nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_ifrsfull-2019EquityMember" unitRef="USD" decimals="-6">358000000</nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">291000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">1078000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-313000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-787000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-915000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">308000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">273000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">1188000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">340000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">1137000000</nvs:GrossDeferredTaxAssets>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-38000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-25000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-797000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-2343000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">212000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">25000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">2502000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">159000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">3722000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">474000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-818000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">23000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-3248000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-2159000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">2446000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">287000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">7000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">255000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-248000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-273000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-31000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-21000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-113000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">75000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">273000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">10000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">507000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-408000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-5000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-164000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-497000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-1314000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">71000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">35000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-34000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">2658000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">1344000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-36000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">2175000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">805000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-166000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">298000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">26000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-1370000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-1271000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">24000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">2596000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">1325000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">2209000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">9799000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">9460000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">10219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">2190000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.02</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">3241000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">3433000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">3414000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember" unitRef="USD" decimals="-6">36732000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember" unitRef="USD" decimals="-6">35684000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember" unitRef="USD" decimals="-6">33491000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">11927000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">11761000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">11260000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">218000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">25000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">227000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">-45000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">33000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">120000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">250000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">220000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="Pure" decimals="5">0.01750</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="Pure" decimals="5">0.99852</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="USD" decimals="-6">996000000</ifrs-full:BondsIssued>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="USD" decimals="-6">1245000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="Pure" decimals="5">0.02000</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="Pure" decimals="5">0.99909</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="USD" decimals="-6">1500000000</ifrs-full:NotionalAmount>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="Pure" decimals="5">0.02200</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="Pure" decimals="5">0.99869</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="USD" decimals="-6">1493000000</ifrs-full:BondsIssued>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="USD" decimals="-6">1213000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="Pure" decimals="5">0.02750</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="Pure" decimals="5">0.97712</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="Pure" decimals="5">0.00000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="EUR" decimals="-6">1850000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="Pure" decimals="5">0.99354</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="USD" decimals="-6">2255000000</ifrs-full:BondsIssued>
  <nvs:BorrowingsInterestRateStepUp contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="Pure" decimals="4">0.0025</nvs:BorrowingsInterestRateStepUp>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">1006000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">345000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">2573000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">2214000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">1953000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">714000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">684000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">15848000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">12889000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">10888000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">7861000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">194000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">184000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">1563000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">1421000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">38000000</ifrs-full:Borrowings>
  <nvs:CashInflowForSaleAndLeaseback contextRef="AR_D-CurrentYear-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-8">-700000000</nvs:CashInflowForSaleAndLeaseback>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-6">96000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-6">37000000</ifrs-full:RightofuseAssets>
  <ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions contextRef="AR_D-CurrentYear-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-6">478000000</ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">47798000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.53</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">46103000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.59</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">17259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">18715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">17933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">19725000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">19713000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">18032000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">40391000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.45</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">29389000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.38</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:ProceedsFromSalesOfInterestsInAssociates contextRef="AR_D-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="USD" decimals="-6">12855000000</ifrs-full:ProceedsFromSalesOfInterestsInAssociates>
  <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations contextRef="AR_D-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="USD" decimals="-6">12994000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
  <nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="AR_I-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="Pure" decimals="3">0.365</nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
  <nvs:PreTaxProfitLossFromDivestmentOfBusiness contextRef="AR_I-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="USD" decimals="-8">5800000000</nvs:PreTaxProfitLossFromDivestmentOfBusiness>
  <nvs:PercentageOfShareCapitalInTenderOffer contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="2">1.00</nvs:PercentageOfShareCapitalInTenderOffer>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="0">41</nvs:CashOfferPerOrdinaryShare>
  <nvs:CashOfferPerADS contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="0">82</nvs:CashOfferPerADS>
  <nvs:NumberOfOrdinarySharePerADS contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="0">2</nvs:NumberOfOrdinarySharePerADS>
  <nvs:ValueOfEquity contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">3900000000</nvs:ValueOfEquity>
  <nvs:PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="2">0.97</nvs:PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">3900000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <nvs:PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="3">0.018</nvs:PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer>
  <nvs:ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-6">60000000</nvs:ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer>
  <nvs:TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="3">0.987</nvs:TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">1900000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">2000000000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">2500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">600000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:RevenueOfAcquiree contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">400000000</ifrs-full:RevenueOfAcquiree>
  <nvs:RevenueOfAcquireeFullYear contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">400000000</nvs:RevenueOfAcquireeFullYear>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-Transaction-AAA-Dec2020_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-Avexis_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="0">218</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">8700000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">7200000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">1500000000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">1600000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">300000000</nvs:OtherNetAssets>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="0">24</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">2100000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">2100000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">1500000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">1500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">300000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">300000000</nvs:OtherNetAssets>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">600000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:NumberOfContractsWithRelatedParties contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SparkTherapeuticsInc.Member" unitRef="Pure" decimals="0">1</nvs:NumberOfContractsWithRelatedParties>
  <nvs:CustomersWithNetSalesOverFivePercent contextRef="AR_D-CurrentYear">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018. The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively).</nvs:CustomersWithNetSalesOverFivePercent>
  <nvs:ConcentrationOfMajorPlansGeographic contextRef="AR_D-CurrentYear">The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#x2019;s total DBO for pension plans.</nvs:ConcentrationOfMajorPlansGeographic>
  <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
  <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
  <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">2010</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">2020</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2012</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2022</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2012</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2042</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2024</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2044</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">2021</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2026</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2029</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2035</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2045</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2016</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2023</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2016</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2028</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">2020</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2022</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">2021</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2018</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2023</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2018</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2030</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2018</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2038</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during February or March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember">Associates in certain countries and certain key executives worldwide are encouraged to invest their Annual Incentive in a share savings plan. Under the share savings plan, participants may elect to receive their relevant compensation fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &#x201C;Select&#x201D; are not eligible to receive ESOP matching shares starting with the 2017 performance period.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLeveragedShareSavingsPlanMember">The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e., one share awarded for each invested share). In the United States, both the LSSP award and the corresponding match are cash settled.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectMember">The equity plan &#x201C;Select&#x201D; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201C;Select&#x201D;. The equity plan &#x201C;Select&#x201D; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. Tradable share options expire on their 10th anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the 10th anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets. Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period. The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. Starting in 2019, for new grants the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember">The LTRPP is an equity plan for the Novartis ECN and NTLs. The last grant under this plan was made in 2018. The LTRPP performance criteria are based on variables that can be observed in the market, which is the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies is calculated as described in the LTPP section above.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationSpecialShareAwardsMember">Selected associates, excluding the ECN members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the &#xAC;organization. Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2020, 2019 and 2018. In addition, in 2020, 2019 and 2018, Board members received &#xAC;unrestricted shares as part of their regular compensation.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;1. Significant accounting policies&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&amp;#x2019; financial statements incorporated into the Group&amp;#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&amp;#x2019;s voting interest). Consolidated entities are also referred to as &amp;#x201c;subsidiaries.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&amp;#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Balance sheets using year-end exchange rates&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Distribution of Alcon Inc. to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&amp;#x2019;s business (the &amp;#x201c;Alcon business&amp;#x201d;) to be reported as discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &amp;#x201c;Other expense&amp;#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &amp;#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&amp;#x201d; in the income statement of discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&amp;#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&amp;#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional disclosures, refer to &amp;#x201c;Note 2. Significant transactions&amp;mdash;Significant transactions in 2019&amp;mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&amp;#x201d; and &amp;#x201c;Note 30. Discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for property, plant and equipment:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Furniture and vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Computer hardware&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&amp;#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &amp;#x201c;net sales&amp;#x201d; or &amp;#x201c;other income,&amp;#x201d; depending on the nature of and underlying asset to the lease arrangement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Prior to January 1, 2019, the Group applied the following accounting policies for leases: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The section &amp;#x201c;&amp;mdash;Impact of adopting significant new IFRS standards in 2019&amp;#x201d; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &amp;#x201c;Other&amp;#x201d; category, and amortized once available for use. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold" &lt;br&gt;&lt;/br&gt; or "Research &lt;br&gt;&lt;/br&gt; and development" &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including &lt;br&gt;&lt;/br&gt;computer software) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the respective &lt;br&gt;&lt;/br&gt; functional expense &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &amp;#x201c;Research and development.&amp;#x201d; Once a project included in IPR&amp;amp;D has been successfully developed, it is transferred to the &amp;#x201c;Currently marketed products&amp;#x201d; category. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&amp;#x2019;s activities with regard to: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected future cash flows&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Long-term sales forecasts &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Profit margins&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Probability of obtaining regulatory approval&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Future tax rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate terminal growth rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate discount rate&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&amp;#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of associated companies accounted for at equity&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &amp;#x201c;Income from associated companies.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other income&amp;#x201d; and &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &amp;#x201c;solely payment of principal and interest&amp;#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &amp;#x201c;Other financial income and expense.&amp;#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &amp;#x201c;Other income&amp;#x201d; for gains and &amp;#x201c;Other expense&amp;#x201d; for losses. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other financial income&amp;#x201d; in the consolidated income statement, depending on the nature of the item. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&amp;#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&amp;#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &amp;#x201c;Cost of goods sold&amp;#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &amp;#x201c;Cost of goods sold.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&amp;#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &amp;#x201c;Selling, general and administration&amp;#x201d; expenses. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &amp;#x201c;Cost of goods sold&amp;#x201d; for currently marketed products and in &amp;#x201c;Research and development&amp;#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other expense,&amp;#x201d; depending on their nature. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent liabilities in &amp;#x201c;Interest expense&amp;#x201d; and for contingent assets as interest income recognized in the consolidated income statement within &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined ben&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;efit pension plans and&amp;nbsp;other&amp;nbsp;post-employment benefits&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &amp;#x201c;Other expense&amp;#x201d; or &amp;#x201c;Other income.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&amp;nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &amp;#x201c;Retained earnings&amp;#x201d; in the consolidated statement of changes in equity. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &amp;#x201c;Net sales&amp;#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&amp;#x2019;s estimated inventory levels. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&amp;#x201c;Other revenue&amp;#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &amp;#x201c;Research and development&amp;#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&amp;#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statements. Corresponding releases are recorded in &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&amp;#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Taxes&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&amp;#x2019;s retained earnings are only taken into account when a dividend has been planned. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combination amendments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2019: &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 16 Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Results of our impact assessment: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As a lessor, the Group had no significant impact upon adoption. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;For additional significant accounting policies applicable to the discontinued operations business see Note 30. &lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&amp;#x2019;s voting interest). Consolidated entities are also referred to as &amp;#x201c;subsidiaries.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&amp;#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Balance sheets using year-end exchange rates&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
  <nvs:DistributionByWayOfDivindendInKindToShareholders contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Distribution of Alcon Inc. to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&amp;#x2019;s business (the &amp;#x201c;Alcon business&amp;#x201d;) to be reported as discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &amp;#x201c;Other expense&amp;#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &amp;#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&amp;#x201d; in the income statement of discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&amp;#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&amp;#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional disclosures, refer to &amp;#x201c;Note 2. Significant transactions&amp;mdash;Significant transactions in 2019&amp;mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&amp;#x201d; and &amp;#x201c;Note 30. Discontinued operations.&amp;#x201d; &lt;/div&gt;</nvs:DistributionByWayOfDivindendInKindToShareholders>
  <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for property, plant and equipment:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Furniture and vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Computer hardware&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
  <nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Furniture and vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Computer hardware&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&amp;#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &amp;#x201c;net sales&amp;#x201d; or &amp;#x201c;other income,&amp;#x201d; depending on the nature of and underlying asset to the lease arrangement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Prior to January 1, 2019, the Group applied the following accounting policies for leases: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The section &amp;#x201c;&amp;mdash;Impact of adopting significant new IFRS standards in 2019&amp;#x201d; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
  <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &amp;#x201c;Other&amp;#x201d; category, and amortized once available for use. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold" &lt;br&gt;&lt;/br&gt; or "Research &lt;br&gt;&lt;/br&gt; and development" &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including &lt;br&gt;&lt;/br&gt;computer software) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the respective &lt;br&gt;&lt;/br&gt; functional expense &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock>
  <nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold" &lt;br&gt;&lt;/br&gt; or "Research &lt;br&gt;&lt;/br&gt; and development" &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including &lt;br&gt;&lt;/br&gt;computer software) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the respective &lt;br&gt;&lt;/br&gt; functional expense &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock>
  <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock contextRef="AR_D-CurrentYear">&lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &amp;#x201c;Research and development.&amp;#x201d; Once a project included in IPR&amp;amp;D has been successfully developed, it is transferred to the &amp;#x201c;Currently marketed products&amp;#x201d; category. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock>
  <nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&amp;#x2019;s activities with regard to: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected future cash flows&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Long-term sales forecasts &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Profit margins&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Probability of obtaining regulatory approval&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Future tax rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate terminal growth rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate discount rate&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&amp;#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock>
  <nvs:DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of associated companies accounted for at equity&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &amp;#x201c;Income from associated companies.&amp;#x201d; &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock>
  <nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock>
  <nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other income&amp;#x201d; and &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &amp;#x201c;solely payment of principal and interest&amp;#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &amp;#x201c;Other financial income and expense.&amp;#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &amp;#x201c;Other income&amp;#x201d; for gains and &amp;#x201c;Other expense&amp;#x201d; for losses. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other financial income&amp;#x201d; in the consolidated income statement, depending on the nature of the item. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock>
  <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&amp;#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&amp;#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &amp;#x201c;Cost of goods sold&amp;#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &amp;#x201c;Cost of goods sold.&amp;#x201d; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
  <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&amp;#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &amp;#x201c;Selling, general and administration&amp;#x201d; expenses. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &amp;#x201c;Cost of goods sold&amp;#x201d; for currently marketed products and in &amp;#x201c;Research and development&amp;#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other expense,&amp;#x201d; depending on their nature. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent liabilities in &amp;#x201c;Interest expense&amp;#x201d; and for contingent assets as interest income recognized in the consolidated income statement within &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined ben&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;efit pension plans and&amp;nbsp;other&amp;nbsp;post-employment benefits&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &amp;#x201c;Other expense&amp;#x201d; or &amp;#x201c;Other income.&amp;#x201d; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&amp;nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &amp;#x201c;Retained earnings&amp;#x201d; in the consolidated statement of changes in equity. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &amp;#x201c;Net sales&amp;#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&amp;#x2019;s estimated inventory levels. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&amp;#x201c;Other revenue&amp;#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
  <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &amp;#x201c;Research and development&amp;#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&amp;#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
  <ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statements. Corresponding releases are recorded in &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Taxes&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&amp;#x2019;s retained earnings are only taken into account when a dividend has been planned. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combination amendments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2019: &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 16 Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Results of our impact assessment: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As a lessor, the Group had no significant impact upon adoption. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;For additional significant accounting policies applicable to the discontinued operations business see Note 30. &lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
  <nvs:DisclosureOfSignificantTransactionsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;2. Significant transactions&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of The&amp;nbsp;Medicines Company&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&amp;#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&amp;#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Results of operations since the date of acquisition were not material.&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &amp;ndash; acquisition of the Japanese business of Aspen Global Incorporated &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Aspen&amp;#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consists of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets, USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. Results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &amp;ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million), not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the Group&amp;#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Assets of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Liabilities of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other non-current &lt;br&gt;&lt;/br&gt;liabilities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April 9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &amp;#x201c;ALC.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&amp;#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&amp;#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; April 8, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net assets derecognized &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derecognition of distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Difference between net assets and distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Recognition of Alcon Inc. shares obtained &lt;br&gt;&lt;/br&gt;through consolidated foundations &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;273 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation gains recycled into &lt;br&gt;&lt;/br&gt;the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs recognized in the consolidated income statement&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; See Note 30 for additional information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For additional disclosures on discontinued operations, refer to Note 30.&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of IFM Tre, Inc. &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&amp;#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gut-directed molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangible assets, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of &lt;i&gt;Xiidra&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with &lt;i&gt;Xiidra&lt;/i&gt; (lifitegrast ophthalmic solution) 5% worldwide. &lt;i&gt;Xiidra&lt;/i&gt; is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration is USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimates that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2018&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of Advanced Accelerator Applications S.A.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A. (AAA), a company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD&amp;nbsp;41 per share and USD&amp;nbsp;82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer valued AAA&amp;#x2019;s equity at USD&amp;nbsp;3.9 billion, on a fully diluted basis. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of January 19, 2018, the expiration date of the tender offer, approximately 97% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs (hereinafter collectively referred to as &amp;#x201c;the outstanding shares&amp;#x201d;), were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the outstanding shares tendered in the offer. On January 22, 2018, Novartis commenced a subsequent offering period that expired on January 31, 2018. As of the expiration of the subsequent offering period, an additional 1.8% of the outstanding shares were validly tendered. Novartis accepted and paid approximately USD 60 million, resulting in an increase in Novartis ownership in AAA to 98.7%. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 3.9 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.9 billion, consisting of USD 2.5 billion intangible assets, USD 0.6 billion net deferred tax liabilities, and goodwill of approximately USD 2.0 billion. In 2018, from the date of the acquisition, the business generated net sales of USD 0.4 billion. Management estimated that net sales for the entire year of 2018 would have amounted to USD 0.4 billion had AAA been acquired at the beginning of 2018. The 2018 results from operations since the acquisition were not material. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of December 31, 2020, Novartis held 99.2% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines &amp;ndash; including &lt;i&gt;Lutathera&lt;/i&gt; (USAN: lutetium Lu 177 dotatate/INN: lutetium ( &lt;sup&gt;177&lt;/sup&gt;Lu) oxodotreotide), a first-in-class radioligand therapy product for neuroendocrine tumors &amp;ndash; and a portfolio of diagnostic products. Radiopharmaceuticals, such as &lt;i&gt;Lutathera&lt;/i&gt;, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of AveXis, Inc.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On April 6, 2018, Novartis entered into an agreement and plan of merger with AveXis, Inc., a US-based clinical stage gene therapy company, under which Novartis commenced on April 17, 2018, a tender offer to purchase all outstanding common stock of AveXis, Inc. for USD 218 per share in cash. On May 15, 2018, Novartis completed the acquisition of the common stock of AveXis, Inc. and paid a total of USD 8.7 billion. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 8.7 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.2 billion, consisting of USD 8.5 billion intangible assets, USD 1.6 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 1.5 billion. The 2018 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;AveXis, Inc. is focused on developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. AveXis, Inc.&amp;#x2019;s initial product candidate, AVXS-101, is a proprietary gene therapy currently in development for the treatment of spinal muscular atrophy (SMA) type 1 &amp;ndash; the leading genetic cause of infant mortality &amp;ndash; and SMA types 2 and 3. In addition, AveXis, Inc. has a pipeline of other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of Endocyte, Inc.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On October 18, 2018, Novartis entered into an agreement and plan of merger with Endocyte, Inc. (Endocyte), a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. The transaction was completed on December 21, 2018. Under the terms of the agreement, Novartis acquired all outstanding shares of Endocyte common stock for USD 24 per share. The total consideration amounted to USD 2.1 billion. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 2.1 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.5 billion, consisting of USD 1.5 billion intangible assets, USD 0.3 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 0.6 billion. The purchase price allocation was preliminary at December 31, 2018, as the transaction closed on December 21, 2018, which was close to the Group&amp;#x2019;s year-end and therefore did not provide sufficient time to complete the valuation of the intangible assets, deferred taxes, assumed liabilities and goodwill. During 2019, there were no significant revisions to the purchase price allocation. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Endocyte uses drug conjugation technology to develop targeted therapies with companion imaging agents, including 177Lu-PSMA-617, a potential first-in-class investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Corporate &amp;ndash; divestment of 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;On June 1, 2018, the transaction closed and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;For significant transactions in 2019 for discontinued operations, see Note 30. There were no significant transactions in 2020 for discontinued operations. &lt;/div&gt;</nvs:DisclosureOfSignificantTransactionsTextBlock>
  <nvs:DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; April 8, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net assets derecognized &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derecognition of distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Difference between net assets and distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Recognition of Alcon Inc. shares obtained &lt;br&gt;&lt;/br&gt;through consolidated foundations &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;273 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation gains recycled into &lt;br&gt;&lt;/br&gt;the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs recognized in the consolidated income statement&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; See Note 30 for additional information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock>
  <nvs:DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Assets of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Liabilities of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other non-current &lt;br&gt;&lt;/br&gt;liabilities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group. &lt;/div&gt;</nvs:DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock>
  <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;3. Segmentation of key figures 2020, 2019 and 2018&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The reporting segments are as follows:&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Immunology, Hepatology and Dermatology; Ophthalmology; Neuroscience; Cardiovascular, Renal and Metabolism; Respiratory; and Established Medicines. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Novartis Technical Operations organization manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Novartis Business Services (NBS) is our shared services organization that delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources, and financial reporting and accounting operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Following the February 28, 2019, shareholders&amp;#x2019; approval of the spin-off of the Alcon business (refer to Notes 1, 2 and 30 for further details), the Group reported its consolidated financial statements as &amp;#x201c;continuing operations&amp;#x201d; and &amp;#x201c;discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Continuing operations comprise the activities of the Innovative Medicines and Sandoz Divisions, and the continuing Corporate activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discontinued operations include the operational results from the Alcon eye care devices business and certain corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1, 2 and 30 for further details). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&amp;#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated income statements&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;058&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;896&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;636&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 34&amp;nbsp;777&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;862&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;742&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;831&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;488&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;043&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;912&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;080&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 153 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 335 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;180&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 741&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 177&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;633&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 890&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;951&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&amp;nbsp;589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;675&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;629&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;113 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;395&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated balance sheets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 83&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;225&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 32&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 30&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 132&amp;nbsp;059&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 118&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;75&amp;nbsp;393&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 56&amp;nbsp;666&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;640&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;664&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 468&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 81&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;849&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 549&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant &lt;br&gt;&lt;/br&gt;and equipment &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 926 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 229 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 217 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 110 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;265 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66&amp;nbsp;808&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and &lt;br&gt;&lt;/br&gt;intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;235 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 647 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 68 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 85 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 52 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;425 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 767 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;430 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;509 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;632 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;644 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 44 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 55 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents, marketable securities, &lt;br&gt;&lt;/br&gt;commodities, time deposits and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current income tax and deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Excluding the impact of business acquisitions &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2020, 2019 and 2018, and for selected non-current assets for the years ended December 31, 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 800&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 795&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;972&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;575&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 309&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;953&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 47&amp;nbsp;798&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&amp;nbsp;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&amp;nbsp;389&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third party from continuing operations by location of customer &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&amp;#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region &lt;sup&gt;1&lt;/sup&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 &lt;br&gt;&lt;/br&gt; to 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 &lt;br&gt;&lt;/br&gt; to 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;458&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;643&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;363&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 772&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 784&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;089&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;626&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;414&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&amp;nbsp;684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;416&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;070&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;711&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;911&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;410&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;776&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 361&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 393&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Voltaren/Cataflam&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 360&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 417&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;303&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis, psoriatic &lt;br&gt;&lt;/br&gt; arthritis and &lt;br&gt;&lt;/br&gt; non-radiographic axial &lt;br&gt;&lt;/br&gt; spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;516 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;479 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;995 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;277 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;497 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 833 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 905 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;738 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 569 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 973 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;542 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) and nasal polyps &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 879&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 964&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 461&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 473 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 873 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;331 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;551 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 801 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;726 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 704&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 691 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 725 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;416 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 481 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 857 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;338 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 978&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 304 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 367 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 671 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;967&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;925&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2018&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;765&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;576&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;674 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;837 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 770&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 581 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 593 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;174 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 457 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 698 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;155 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 578&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 556 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 472 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 262 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 292 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 554 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Travoprost Group &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Reduction of elevated intraocular &lt;br&gt;&lt;/br&gt; pressure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 323 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 517 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;654&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;244&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;928&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The product portfolio of Sandoz is widely spread in 2020, 2019 and 2018.&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; other revenue&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 300&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 128&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
  <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated income statements&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;058&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;896&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;636&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 34&amp;nbsp;777&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;862&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;742&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;831&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;488&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;043&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;912&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;080&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 153 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 335 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;180&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 741&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 177&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;633&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 890&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;951&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&amp;nbsp;589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;675&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;629&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;113 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;395&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
  <nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated balance sheets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 83&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;225&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 32&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 30&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 132&amp;nbsp;059&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 118&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;75&amp;nbsp;393&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 56&amp;nbsp;666&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;640&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;664&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 468&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 81&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;849&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 549&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant &lt;br&gt;&lt;/br&gt;and equipment &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 926 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 229 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 217 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 110 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;265 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66&amp;nbsp;808&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and &lt;br&gt;&lt;/br&gt;intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;235 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 647 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 68 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 85 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 52 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;425 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 767 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;430 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;509 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;632 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;644 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 44 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 55 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents, marketable securities, &lt;br&gt;&lt;/br&gt;commodities, time deposits and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current income tax and deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Excluding the impact of business acquisitions &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 800&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 795&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;972&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;575&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 309&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;953&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 47&amp;nbsp;798&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&amp;nbsp;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&amp;nbsp;389&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third party from continuing operations by location of customer &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock>
  <nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region &lt;sup&gt;1&lt;/sup&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 &lt;br&gt;&lt;/br&gt; to 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 &lt;br&gt;&lt;/br&gt; to 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;458&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;643&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;363&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 772&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 784&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;089&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;626&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;414&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&amp;nbsp;684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;416&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;070&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;711&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;911&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;410&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;776&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 361&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 393&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Voltaren/Cataflam&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 360&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 417&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;303&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">&lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis, psoriatic &lt;br&gt;&lt;/br&gt; arthritis and &lt;br&gt;&lt;/br&gt; non-radiographic axial &lt;br&gt;&lt;/br&gt; spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;516 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;479 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;995 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;277 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;497 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 833 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 905 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;738 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 569 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 973 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;542 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) and nasal polyps &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 879&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 964&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 461&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 473 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 873 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;331 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;551 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 801 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;726 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 704&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 691 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 725 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;416 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 481 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 857 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;338 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 978&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 304 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 367 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 671 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;967&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;925&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2018&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;765&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;576&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;674 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;837 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 770&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 581 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 593 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;174 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 457 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 698 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;155 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 578&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 556 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 472 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 262 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 292 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 554 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Travoprost Group &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Reduction of elevated intraocular &lt;br&gt;&lt;/br&gt; pressure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 323 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 517 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;654&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;244&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;928&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; other revenue&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 300&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 128&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock>
  <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;4. Associated companies&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 601&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;GlaxoSmithKline Consumer &lt;br&gt;&lt;/br&gt;Healthcare Holdings Ltd., UK &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;557 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;353 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies related to continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 565&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has a significant investment in Roche Holding AG, Basel (Roche), as well as certain other smaller investments that are accounted for as associated companies. The investment in GlaxoSmithKline Consumer Healthcare Holdings Ltd., Brentford, Middlesex, UK, was divested on June 1, 2018, to GlaxoSmithKline plc, Great Britain. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 225&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&amp;#x2019;s holding in Roche voting shares was 33.3% at December 31, 2020, 2019 and 2018. This investment represents approximately 6.2% of Roche&amp;#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since full-year 2020 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&amp;#x2019;s share of Roche&amp;#x2019;s net income. Any differences between these estimates and actual results will be adjusted in the Group&amp;#x2019;s 2021 consolidated financial statements when available. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2019, and for the six months ended June 30, 2020 (since full-year 2020 data is not yet available): &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Current assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 56.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Net income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2020, balance sheet value allocation is as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche&amp;#x2019;s estimated net assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of reappraised intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Implicit Novartis goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current value of share in net identifiable assets &lt;br&gt;&lt;/br&gt;and goodwill &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;935 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated equity accounting adjustments and translation effects less dividends received&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2020, dividends received from Roche in relation to the distribution of its 2019 net income amounted to USD&amp;nbsp;487 million (2019: USD 460 million in relation to the distribution of its 2018 net income). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated income statement effects from applying Novartis accounting principles for this investment in 2020, 2019 and 2018 are as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 913 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 799 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets, net of taxes &lt;br&gt;&lt;/br&gt;of USD 26 million (2019: USD 24 &lt;br&gt;&lt;/br&gt;million; 2018: USD 40 million) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;172 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;162 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;148 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Partial release of deferred tax liability recognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December&amp;nbsp;31, 2020, was USD&amp;nbsp;18.8 billion (2019: USD&amp;nbsp;16.9 billion). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;GlaxoSmithKline Consumer Healthcare Holdings&amp;nbsp;Ltd.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc, Great Britain (GSK), to divest its 36.5% stake in GSK Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. The divestment transaction closed on June 1, 2018, and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. See Note 2. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;GSK Consumer Healthcare was formed in March 2015 via contribution of businesses from both Novartis and GSK. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Until June 1, 2018, Novartis had a 36.5% interest in GSK Consumer Healthcare and had four of 11 seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis had customary minority rights as well as exit rights at a predefined, market-based pricing mechanism. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated income statement effects from applying Novartis accounting principles for this investment in 2018 are as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of &lt;br&gt;&lt;/br&gt;GSK Consumer Healthcare's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 119 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets and inventory, &lt;br&gt;&lt;/br&gt;net of taxes of USD 1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pre-tax gain on divestment of GSK Consumer Healthcare&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
  <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 601&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;GlaxoSmithKline Consumer &lt;br&gt;&lt;/br&gt;Healthcare Holdings Ltd., UK &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;557 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;353 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies related to continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 565&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
  <nvs:DisclosureOfAssociatesBalanceSheetTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 225&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssociatesBalanceSheetTableTextBlock>
  <nvs:AssociatesSummarizedFinancialInformationTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Current assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 56.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Net income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AssociatesSummarizedFinancialInformationTableTextBlock>
  <nvs:PurchasePriceAllocationAssociatesTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche&amp;#x2019;s estimated net assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of reappraised intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Implicit Novartis goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current value of share in net identifiable assets &lt;br&gt;&lt;/br&gt;and goodwill &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;935 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated equity accounting adjustments and translation effects less dividends received&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:PurchasePriceAllocationAssociatesTableTextBlock>
  <nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 913 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 799 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets, net of taxes &lt;br&gt;&lt;/br&gt;of USD 26 million (2019: USD 24 &lt;br&gt;&lt;/br&gt;million; 2018: USD 40 million) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;172 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;162 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;148 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Partial release of deferred tax liability recognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock>
  <nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of &lt;br&gt;&lt;/br&gt;GSK Consumer Healthcare's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 119 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets and inventory, &lt;br&gt;&lt;/br&gt;net of taxes of USD 1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pre-tax gain on divestment of GSK Consumer Healthcare&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock>
  <ifrs-full:DisclosureOfInterestExpenseExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;5. Interest expense and&amp;nbsp;other&amp;nbsp;financial&amp;nbsp;income&amp;nbsp;and&amp;nbsp;expense&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest expense&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;708&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other financial income and expense&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income and expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfInterestExpenseExplanatory>
  <nvs:InterestExpenseTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;708&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:InterestExpenseTableTextBlock>
  <nvs:OtherFinancialIncomeAndExpenseTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income and expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OtherFinancialIncomeAndExpenseTableTextBlock>
  <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;6. Taxes&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Income before taxes&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;887&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Current and deferred income tax expense&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;961&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;988&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Analysis of tax rate&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or are taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The main elements contributing to the difference between the Group&amp;#x2019;s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary) and the effective tax rate are shown in the following table: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of tax losses &lt;br&gt;&lt;/br&gt;brought forward from prior periods &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of &lt;br&gt;&lt;/br&gt;contingent consideration liability &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change &lt;br&gt;&lt;/br&gt;on current and deferred &lt;br&gt;&lt;/br&gt;tax assets and liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-off of deferred tax assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of &lt;br&gt;&lt;/br&gt;write-down of investments in subsidiaries &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate for continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%). &lt;br&gt;&lt;/br&gt; In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The utilization of tax-loss carry-forwards lowered the tax charge by USD&amp;nbsp;29 million in 2020, by USD&amp;nbsp;11 million in 2019, and by USD&amp;nbsp;19 million in 2018.&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For the amount of taxes attributable to discontinued operations, see Note 30.&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <nvs:IncomeBeforeTaxesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;887&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:IncomeBeforeTaxesTableTextBlock>
  <nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;961&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;988&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock>
  <nvs:AnalysisOfTaxRateTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of tax losses &lt;br&gt;&lt;/br&gt;brought forward from prior periods &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of &lt;br&gt;&lt;/br&gt;contingent consideration liability &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change &lt;br&gt;&lt;/br&gt;on current and deferred &lt;br&gt;&lt;/br&gt;tax assets and liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-off of deferred tax assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of &lt;br&gt;&lt;/br&gt;write-down of investments in subsidiaries &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate for continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%). &lt;br&gt;&lt;/br&gt; In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AnalysisOfTaxRateTableTextBlock>
  <ifrs-full:EarningsPerShareExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;7. Earnings per share&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;277&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.00&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.06&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;No options were excluded from the calculation of diluted EPS in 2020, 2019 or 2018, as all options were dilutive in all years. &lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
  <nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;277&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.00&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.06&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;8. Changes in consolidated statements of&amp;nbsp;comprehensive income&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated statements of comprehensive income include the Group&amp;#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&amp;#x2019;s consolidated balance sheet which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of tax. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; on financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Actuarial &lt;br&gt;&lt;/br&gt; gains/(losses) &lt;br&gt;&lt;/br&gt; from defined &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Cumulative &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; effects &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; attributable to &lt;br&gt;&lt;/br&gt; Novartis AG &lt;br&gt;&lt;/br&gt; shareholders &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non- &lt;br&gt;&lt;/br&gt; controlling &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2017, as previously reported&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 395&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;361&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 9 on retained &lt;br&gt;&lt;/br&gt;earnings and OCI &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Restated value adjustments at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash flow &lt;br&gt;&lt;/br&gt;hedges, net of taxes of USD -1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -5 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD 69 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 415&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 81&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;478&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash &lt;br&gt;&lt;/br&gt;flow hedges &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD 47 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -313 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 398&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;686&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -36 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -3 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;386&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;448&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the &lt;br&gt;&lt;/br&gt;consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other &lt;br&gt;&lt;/br&gt;comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;8.1) In 2020, no currency translation losses or gains were recycled through the income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, cumulative currency translation gains of USD&amp;nbsp;129 million were recycled through the income statement mainly as a result of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders. See Notes 2 and 30. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2018, cumulative currency translation losses of USD&amp;nbsp;946 million were recycled through the income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. See Notes 2 and 4. &lt;/div&gt;</nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock>
  <nvs:ScheduleOfComprehensiveIncomeTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; on financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Actuarial &lt;br&gt;&lt;/br&gt; gains/(losses) &lt;br&gt;&lt;/br&gt; from defined &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Cumulative &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; effects &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; attributable to &lt;br&gt;&lt;/br&gt; Novartis AG &lt;br&gt;&lt;/br&gt; shareholders &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non- &lt;br&gt;&lt;/br&gt; controlling &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2017, as previously reported&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 395&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;361&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 9 on retained &lt;br&gt;&lt;/br&gt;earnings and OCI &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Restated value adjustments at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash flow &lt;br&gt;&lt;/br&gt;hedges, net of taxes of USD -1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -5 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD 69 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 415&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 81&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;478&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash &lt;br&gt;&lt;/br&gt;flow hedges &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD 47 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -313 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 398&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;686&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -36 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -3 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;386&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;448&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the &lt;br&gt;&lt;/br&gt;consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other &lt;br&gt;&lt;/br&gt;comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfComprehensiveIncomeTableTextBlock>
  <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;9. Property, plant and equipment&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 117 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 168 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 332 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 847&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;465&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 695&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 555&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;377&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;58 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;004&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;063&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;955&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;570&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 696&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;009&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;924&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;541&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;948&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
  <nvs:PropertyPlantAndEquipmentTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 117 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 168 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 332 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 847&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;465&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 695&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 555&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;377&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;58 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;004&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;063&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;955&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;570&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 696&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;009&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;924&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;541&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;948&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:PropertyPlantAndEquipmentTableTextBlock>
  <ifrs-full:DisclosureOfLeasesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;10. Right-of-use assets and lease liabilities&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of the right-of-use assets of continuing operations: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31 &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; No impairment charge was recorded in 2020 (2019: nil). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the right-of-use assets carrying value and depreciation charge of continuing operations at December 31, 2020 and 2019, by underlying class of asset: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 528&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the lease liabilities of continuing operations by maturity at December 31, 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 295&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 226&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2020 and December 31, 2019, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&amp;#x2019;s most material lease with a lease term extension, representing a lease liability value of USD 0.6 billion (2019: USD 0.6 billion), has a determined lease term end date of 2071 (2019: 2071). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the Group completed sale and leaseback transactions for certain property, plant and equipment as part of its plans to consolidate sites. Transactions resulted in net cash inflows of USD 0.7 billion and the recognition of USD 96 million of lease liabilities, and USD 37 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained for a period of one to five years, with two five-year extension periods for certain right-of-use assets. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 478 million. There were no significant sale and leaseback transactions completed in 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table provides additional disclosures related to right-of-use assets and lease liabilities of continuing operations for 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cash outflows for short-term leases &lt;br&gt;&lt;/br&gt;and low-value leases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of interest &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The weighted average interest rate is 3.4% (2019: 3.9%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Included within total net cash flows from operating activities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The net investment held and income from subleasing right-of-use assets were not significant for 2020 and 2019. Income from leasing Novartis property, plant and equipment to third parties for both 2020 and 2019 was not significant. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 30 provides additional disclosures on discontinued operations.&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
  <nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31 &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; No impairment charge was recorded in 2020 (2019: nil). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock>
  <nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 528&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock>
  <nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 295&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 226&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock>
  <nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cash outflows for short-term leases &lt;br&gt;&lt;/br&gt;and low-value leases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of interest &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The weighted average interest rate is 3.4% (2019: 3.9%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Included within total net cash flows from operating activities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock>
  <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;11. Goodwill and intangible assets&lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 276 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;112 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 412&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;572&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 57&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on assets reclassified &lt;br&gt;&lt;/br&gt;out of assets of disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;816 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 421 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 567 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;267&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;322&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;566&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Alcon &lt;br&gt;&lt;/br&gt; brand name &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Marketing &lt;br&gt;&lt;/br&gt; know-how &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;412&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;960&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 69&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;000 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;249 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;980 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;369 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;440 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;960 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;572 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;570 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group &lt;br&gt;&lt;/br&gt;held for sale, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;055&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 254&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;406&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization &lt;br&gt;&lt;/br&gt;on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;184 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;592 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;906 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;813 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 70 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 494 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 419 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 983 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to assets of disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 925&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&amp;nbsp;720&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 520&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 85&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Innovative Medicines and Sandoz Divisions&amp;#x2019; cash-generating units, to which goodwill is allocated, each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following assumptions are used in the calculations:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(As a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br&gt;&lt;/br&gt; Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The discount rates for all divisions consider the Group&amp;#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;&amp;#x201c;Note 1. Significant accounting policies&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the intangible asset and goodwill impairment charges for continuing operations for 2020, 2019 and 2018: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;br&gt;&lt;/br&gt;2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis. &lt;br&gt;&lt;/br&gt;2018 includes an impairment of USD 400 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;amp;D related to the discontinuation of the generic Advair&amp;#xae; development program. &lt;br&gt;&lt;/br&gt;2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, there were no reversals of prior-year impairment charges (2019: USD 37 million; 2018: nil).&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Note 30 provides additional disclosures on discontinued operations.&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
  <nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 276 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;112 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 412&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;572&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 57&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on assets reclassified &lt;br&gt;&lt;/br&gt;out of assets of disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;816 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 421 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 567 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;267&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;322&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;566&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Alcon &lt;br&gt;&lt;/br&gt; brand name &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Marketing &lt;br&gt;&lt;/br&gt; know-how &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;412&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;960&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 69&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;000 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;249 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;980 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;369 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;440 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;960 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;572 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;570 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group &lt;br&gt;&lt;/br&gt;held for sale, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;055&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 254&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;406&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization &lt;br&gt;&lt;/br&gt;on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;184 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;592 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;906 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;813 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 70 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 494 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 419 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 983 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to assets of disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock>
  <nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 925&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&amp;nbsp;720&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 520&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 85&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock>
  <nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(As a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br&gt;&lt;/br&gt; Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock>
  <nvs:IntangibleAssetImpairmentChargesTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;br&gt;&lt;/br&gt;2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis. &lt;br&gt;&lt;/br&gt;2018 includes an impairment of USD 400 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;amp;D related to the discontinuation of the generic Advair&amp;#xae; development program. &lt;br&gt;&lt;/br&gt;2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:IntangibleAssetImpairmentChargesTextBlock>
  <ifrs-full:DisclosureOfDeferredTaxesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;12. Deferred tax assets and liabilities &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Property, &lt;br&gt;&lt;/br&gt; plant and &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and &lt;br&gt;&lt;/br&gt; other benefit &lt;br&gt;&lt;/br&gt; obligations &lt;br&gt;&lt;/br&gt; of associates &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Inventories &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Tax loss &lt;br&gt;&lt;/br&gt; carry- &lt;br&gt;&lt;/br&gt; forwards &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other assets, &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; and accruals &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 212&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;945&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 408&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;422&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;782&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net deferred tax balance related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 858&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 605&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than 12&amp;nbsp;months:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected to have an impact on current tax payable after more than 12 months&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&amp;#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 27 billion in 2020 (2019: USD 26 billion). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Temporary differences on which no deferred tax has been provided as they are permanent in nature related to: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investments in subsidiaries&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill from acquisitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The gross value of tax-loss carry-forwards that have or have not been capitalized as deferred tax assets, with their expiry dates, is as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;780&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 310&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 648&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;986&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward &lt;br&gt;&lt;/br&gt;that expired &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The Basel-Stadt cantonal tax reform was approved by voters in February 2019, with parts of the reform retroactively enacted per January 1, 2019. The newly enacted tax rate resulted in a decrease of the blended cantonal and federal tax rate from 22% to 13%. This change impacted the Group&amp;#x2019;s Basel-Stadt-domiciled operating subsidiaries. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Swiss federal tax reform was approved by voters in May 2019. The enactment of the Swiss federal tax reform required the abolishment of the holding company tax regimes as of January 1, 2020. As a result, the holding company tax rate increased from the current 8% to 13%, effective January 1, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The enactment of these Swiss tax reforms required a revaluation of the deferred tax assets and liabilities to the newly enacted tax rates at the date of enactment. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the impact on the revaluation of deferred assets and liabilities in 2019, as at the respective dates of the enactment of the Swiss tax reforms: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Income &lt;br&gt;&lt;/br&gt; statement &lt;br&gt;&lt;/br&gt; continuing &lt;br&gt;&lt;/br&gt; operations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax asset &lt;br&gt;&lt;/br&gt;and liability revaluation &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized &lt;br&gt;&lt;/br&gt;in consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized in other comprehensive income &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total revaluation of deferred tax assets and liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Related to post-employment benefits &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
  <nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Property, &lt;br&gt;&lt;/br&gt; plant and &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and &lt;br&gt;&lt;/br&gt; other benefit &lt;br&gt;&lt;/br&gt; obligations &lt;br&gt;&lt;/br&gt; of associates &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Inventories &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Tax loss &lt;br&gt;&lt;/br&gt; carry- &lt;br&gt;&lt;/br&gt; forwards &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other assets, &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; and accruals &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 212&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;945&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 408&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;422&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;782&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net deferred tax balance related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 858&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 605&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <nvs:DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected to have an impact on current tax payable after more than 12 months&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock>
  <nvs:TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investments in subsidiaries&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill from acquisitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock>
  <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;780&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 310&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 648&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;986&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward &lt;br&gt;&lt;/br&gt;that expired &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
  <nvs:CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Income &lt;br&gt;&lt;/br&gt; statement &lt;br&gt;&lt;/br&gt; continuing &lt;br&gt;&lt;/br&gt; operations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax asset &lt;br&gt;&lt;/br&gt;and liability revaluation &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized &lt;br&gt;&lt;/br&gt;in consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized in other comprehensive income &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total revaluation of deferred tax assets and liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Related to post-employment benefits &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock>
  <nvs:DisclosureOfFinancialAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;577&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;979&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;901&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfFinancialAssetsTableTextBlock>
  <nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 414&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock>
  <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;14. Inventories&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;840&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;982&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the amount of inventory recognized as an expense in &amp;#x201c;Cost of goods sold&amp;#x201d; in the consolidated income statements from continuing operations: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements from continuing operations: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;702&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received. &lt;/div&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
  <nvs:ScheduleOfInventoryCurrentTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;840&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;982&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfInventoryCurrentTableTextBlock>
  <nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock>
  <nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;702&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock>
  <nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;15. Trade receivables&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;310&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movement in the provision for doubtful trade receivables:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;763&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 161&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month &lt;br&gt;&lt;/br&gt;but less than three months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 118 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months &lt;br&gt;&lt;/br&gt;but less than six months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 102 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 103 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months &lt;br&gt;&lt;/br&gt;but less than one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 77 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 96 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions in the countries in which it operates, particularly in Argentina, Brazil, Greece, Italy, Portugal, Russia, Saudi Arabia, Spain and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from Portugal, Saudi Arabia, Spain and Greece are due directly from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2020 and 2019; the amounts that are past due for more than one year; and the related provisions that have been recorded: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total balance of gross trade &lt;br&gt;&lt;/br&gt;receivables from closely &lt;br&gt;&lt;/br&gt;monitored countries &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;505 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;588 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2020, amounts past due for more than one year are not significant in any of these countries on a standalone basis. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Total trade receivables include amounts denominated in the following major currencies:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;668&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 437&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock>
  <nvs:ProvisionsForTradeReceivablesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;310&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ProvisionsForTradeReceivablesTableTextBlock>
  <nvs:TradeReceivablesProvisionMovementsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TradeReceivablesProvisionMovementsTableTextBlock>
  <nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;763&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 161&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month &lt;br&gt;&lt;/br&gt;but less than three months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 118 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months &lt;br&gt;&lt;/br&gt;but less than six months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 102 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 103 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months &lt;br&gt;&lt;/br&gt;but less than one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 77 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 96 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock>
  <nvs:GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total balance of gross trade &lt;br&gt;&lt;/br&gt;receivables from closely &lt;br&gt;&lt;/br&gt;monitored countries &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;505 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;588 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock>
  <nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;668&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 437&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock>
  <nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;16. Marketable securities, commodities, time&amp;nbsp;deposits, derivative financial instruments, and&amp;nbsp;cash and cash equivalents&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities, time&amp;nbsp;deposits and derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;905&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;908&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;865&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock>
  <nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;905&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock>
  <nvs:CashAndCashEquivalentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;908&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;865&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashAndCashEquivalentsTableTextBlock>
  <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;17. Other current assets&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 544&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 508&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Receivables from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;523&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;680&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
  <nvs:OtherCurrentAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 544&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 508&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Receivables from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;523&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;680&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OtherCurrentAssetsTableTextBlock>
  <nvs:DisclosureOfEquityTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;18. Equity&lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the share capital:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Jan 1, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 969&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 944&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 936&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 875&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the shares:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Number of outstanding shares &lt;br&gt;&lt;/br&gt;(in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;616.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;299.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;317.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital &lt;br&gt;&lt;/br&gt;reduction &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be &lt;br&gt;&lt;/br&gt;canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options &lt;br&gt;&lt;/br&gt;and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 18.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon &lt;br&gt;&lt;/br&gt;employees &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 52.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 59.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;467.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;210.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;256.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.85&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.80&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment &lt;br&gt;&lt;/br&gt;(in USD billion) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.2) The following table summarizes the treasury shares movements:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;897&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;056&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;973&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 730&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 756&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;520&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.3) In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020.&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis was able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;This trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD&amp;nbsp;5 billion share buyback and to repurchase Novartis shares to mitigate dilution related to participation plans of associates. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2018, Novartis entered into a similar irrevocable, non-discretionary arrangements with a bank to repurchase Novartis shares. The commitments under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The commitment under this arrangement amounted to USD 284 million as of December 31, 2018. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.7) Other movements includes, for subsidiaries in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period as well as the restatement of the equity balances of the current year. In 2020, the amount recorded in equity related to hyperinflation accounting was USD 18 million (2019: USD 22 million; 2018: USD 38 million). See Note 29 for additional disclosures. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.8) In 2019, transaction costs of USD 253 million (2018: USD 79 million) net of tax of USD 36 million (2018: USD 20 million), that are directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis shareholders and that would otherwise have been avoided, were recorded as a deduction from equity. See Note 1 for further details. No transaction costs were recorded as a deduction from equity in 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.9) At December 31, 2020, the market maker held 1 million (2019: 13 million; 2018: 11 million) written call options, originally issued as part of the share-based compensation for associates, that have not yet been exercised. The weighted average exercise price of these options is USD 60.09 (2019: USD 63.90; 2018: USD 62.70), and they have contractual lives of 10 years, with remaining lives up to three years (2019: four years; 2018: five years). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2018, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options that are not exercised in exchange for treasury shares. During 2019, this agreement was fully executed. &lt;/div&gt;</nvs:DisclosureOfEquityTextBlock>
  <nvs:MovementInTheShareCapitalTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Jan 1, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 969&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 944&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 936&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 875&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:MovementInTheShareCapitalTableTextBlock>
  <nvs:MovementInTheShareslTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Number of outstanding shares &lt;br&gt;&lt;/br&gt;(in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;616.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;299.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;317.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital &lt;br&gt;&lt;/br&gt;reduction &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be &lt;br&gt;&lt;/br&gt;canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options &lt;br&gt;&lt;/br&gt;and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 18.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon &lt;br&gt;&lt;/br&gt;employees &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 52.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 59.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;467.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;210.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;256.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:MovementInTheShareslTableTextBlock>
  <nvs:DividendTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.85&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.80&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment &lt;br&gt;&lt;/br&gt;(in USD billion) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DividendTableTextBlock>
  <nvs:SummaryOfTreasurySharesMovementsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;897&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;056&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;973&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 730&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 756&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;520&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:SummaryOfTreasurySharesMovementsTableTextBlock>
  <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;19. Non-current financial debt&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Average interest rate 0.3% (2019: 0.2%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The percentage of fixed-rate financial debt to total financial debt was 79% at December 31, 2020, and 82% at December 31, 2019.&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The average interest rate on total financial debt in 2020 was 2.0% (2019: 2.4%).&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 29 contains a maturity table of the Group&amp;#x2019;s future contractual interest payments commitments. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table provides a breakdown of straight bonds:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Coupon &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Currency &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Nominal &lt;br&gt;&lt;/br&gt; amount &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Issuance &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Maturity &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issuer &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issue price &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2010&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.237%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.225%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;495&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.325%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.287%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2044&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.196%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;826&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.134%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2026&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.697%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.250%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.640%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2029&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.502%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.050%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2035&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.479%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.010%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2045&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.029%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.127%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.480%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.800%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.609%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.449%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.109%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.133%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.874%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.500%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.655%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.375%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.957%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.217%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.852%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.909%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.200%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.869%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;493&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97.712%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000% &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.354%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Breakdown by maturity:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;631&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;583&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;991&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Breakdown by currency:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;861&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&amp;nbsp;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 31&amp;nbsp;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values. &lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
  <nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Average interest rate 0.3% (2019: 0.2%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock>
  <nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Coupon &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Currency &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Nominal &lt;br&gt;&lt;/br&gt; amount &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Issuance &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Maturity &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issuer &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issue price &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2010&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.237%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.225%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;495&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.325%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.287%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2044&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.196%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;826&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.134%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2026&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.697%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.250%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.640%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2029&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.502%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.050%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2035&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.479%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.010%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2045&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.029%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.127%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.480%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.800%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.609%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.449%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.109%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.133%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.874%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.500%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.655%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.375%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.957%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.217%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.852%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.909%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.200%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.869%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;493&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97.712%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000% &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.354%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock>
  <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;631&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;583&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;991&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock>
  <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;861&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock>
  <nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&amp;nbsp;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 31&amp;nbsp;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock>
  <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;20. Provisions and other non-current liabilities&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit pension plans &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term employee benefits and deferred compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 637&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other post-employment benefits &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;934&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&amp;#x2019;s financial condition but could be material to the results of operations or cash flows in a given period. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Environmental remediation provisions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movements in the environmental liability provisions:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 761&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary and to continue surveillance at sites where the environmental remediation exposure is less significant. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on a yearly basis and adjusted as necessary. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected timing of the related cash outflows as of December 31, 2020, is currently projected as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br&gt;&lt;/br&gt; cash outflows &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation liability provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&amp;#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 3&amp;#xa0;000 individual product liability cases and certain other legal matters. Plaintiffs&amp;#x2019; alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to the current best belief of Novartis, approximately USD&amp;nbsp;0.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&amp;#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 28 contains additional information on contingencies.&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of significant legal proceedings&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2020. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Investigations and related litigations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&amp;#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for &lt;i&gt;Gilenya&lt;/i&gt;, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a &lt;i&gt;qui tam&lt;/i&gt; complaint, which continue to be vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Government generic pricing antitrust investigations, antitrust class actions&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ), and a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with those agencies&amp;#x2019; investigation into alleged price fixing and market allocation of generic drugs in the US market as well as alleged federal False Claims Act (FCA) violations. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&amp;#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 187 million. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by 54 states and US territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz, engaged in price fixing and market allocation of generic drugs in the US market, and seek damages and injunctive relief. The actions contain product-specific complaints as well as complaints alleging the existence of an overarching industry conspiracy, and assert violations of federal and state antitrust laws as well as consumer protection laws. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Lucentis/Avastin &lt;sup&gt;&amp;#xae;&lt;/sup&gt; matters &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin &lt;sup&gt;&amp;#xae;&lt;/sup&gt; and &lt;i&gt;Lucentis&lt;/i&gt;, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&amp;nbsp;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following the CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims has been asserted in legal proceedings. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to 2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine of EUR 385 million (equivalent to approximately USD 452 million). Novartis paid the fine, again subject to recoupment, and is appealing the FCA&amp;#x2019;s decision. Novartis continues to vigorously contest all claims in Italy and France. Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including Italy and Turkey. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Japan investigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also against NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2018, the Tokyo High Court upheld a not-guilty ruling of the Tokyo District Court for both the former NPKK employee and NPKK. A further appeal by the Tokyo High Public Prosecutor Office remains pending. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;South Korea investigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine in January 2020, and the Prosecutor has appealed the fine. The resolution of inquiries by the DOJ and the US Securities and Exchange Commission (SEC) regarding this matter is described below in &amp;#x201c;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Greece investigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis is providing information to the Greek authorities investigating allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime, from which the Company received a summons in 2018 and 2020. The resolution of inquiries by the DOJ and the SEC regarding this matter is described below in &amp;#x201c;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Antitrust class actions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Exforge&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of &lt;i&gt;Exforge&lt;/i&gt; in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. and the claims are being vigorously contested. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Product liability litigation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Reclast &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 20 US product liability actions involving &lt;i&gt;Reclast&lt;/i&gt; and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Taxotere&amp;#xae; (docetaxel)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz is a defendant in more than 3&amp;#xa0;000 US product liability actions involving Taxotere &lt;sup&gt;&amp;#xae;&lt;/sup&gt; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Amiodarone&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz entities are named in less than five individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Sartans and ranitidine&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Tasigna&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 80 US product liability actions involving &lt;i&gt;Tasigna&lt;/i&gt;, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. The actions are pending in New Jersey state court and in federal courts in various jurisdictions. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other matters&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Average Wholesale Price (AWP) litigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in a putative class action brought by private payors in New Jersey, and vigorously contests those claims. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Aimovig&amp;ndash;Amgen dispute&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2015 and 2017, Novartis and Amgen entered into agreements regarding the development and commercialization of &lt;i&gt;Aimovig&lt;/i&gt;, which the companies co-commercialize in the US and to which Novartis has exclusive rights in all territories outside the US, excluding Japan. Amgen issued a termination notice in April 2019 based on an alleged material breach of the collaboration agreements, and this notice, as well as other ancillary matters, are the subject of legal proceedings between Novartis and Amgen. Novartis disputes Amgen&amp;#x2019;s allegations vigorously. In 2020, the court ruled that Amgen did not have grounds to terminate the 2017 agreement and dismissed that portion of their lawsuit. The collaboration continues during the litigation between the companies, and will remain in force until and unless a final court decision terminates the agreements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Shareholder Derivative Lawsuit&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiff, derivatively as a purported Novartis shareholder on behalf of Novartis, seeks damages and other remedies based on alleged conduct by the corporate and individual defendants. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Concluded legal matters&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;S.D.N.Y. marketing practices investigation and litigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, the US government filed a civil complaint in intervention to an individual &lt;i&gt;qui tam&lt;/i&gt; action against NPC in the USDC for the S.D.N.Y. The complaint, as subsequently amended, asserted federal FCA and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( &lt;i&gt;Lotrel&lt;/i&gt;, &lt;i&gt;Starlix&lt;/i&gt; and &lt;i&gt;Valturna&lt;/i&gt;) allegedly serving as mechanisms to provide kickbacks to HCPs. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. In 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis agreed to pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health and Human Services. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;U.S. Government Foreign Corrupt Practices Act (FCPA) investigations&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, Novartis reached settlements with the DOJ and the SEC resolving all FCPA investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &amp;#x201c;Investigations and related litigations &amp;ndash; Greece investigation,&amp;#x201d; &amp;#x201c;Investigations and related litigations &amp;ndash; South Korea investigation&amp;#x201d; and &amp;#x201c;Investigations and related litigations &amp;ndash; Asia/Russia investigation.&amp;#x201d; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. To resolve the DOJ investigation, both Novartis Hellas S.A.C.I. and Alcon Pte Ltd., a former Novartis subsidiary, entered into separate deferred prosecution agreements (DPA) with the DOJ. The Novartis Hellas DPA contained no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea, which also addressed certain internal controls and books and records issues related to Alcon China&amp;#x2019;s placement of surgical devices. Other developments in Greece and South Korea are described above in &amp;#x201c;Investigations and related litigations &amp;ndash; Greece investigation&amp;#x201d; and &amp;#x201c;Investigations and related litigations &amp;ndash; South Korea investigation,&amp;#x201d; respectively. The matters disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the heading &amp;#x201c;Investigations and related litigations &amp;ndash; Asia/Russia investigation&amp;#x201d; are now concluded. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Enoxaparin&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin. In 2019, Sandoz agreed to pay USD 85 million to resolve the class action. The matter is now concluded. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Summary of product liability, governmental investigations and other legal matters provision movements &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;42 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product liabilities, governmental investigations and other legal matters provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. &lt;/div&gt;</ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
  <ifrs-full:DisclosureOfOtherProvisionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit pension plans &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term employee benefits and deferred compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 637&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other post-employment benefits &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;934&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
  <nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 761&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock>
  <nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br&gt;&lt;/br&gt; cash outflows &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation liability provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock>
  <nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;42 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product liabilities, governmental investigations and other legal matters provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock>
  <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;21. Current financial debt and&amp;nbsp;derivative&amp;nbsp;financial&amp;nbsp;instruments&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates &lt;br&gt;&lt;/br&gt;payable on demand &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;085 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;836 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 0.4% (2019: 0.5%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 5.0% (2019: 12.9%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Details on commercial papers and short term borrowings are provided under &amp;#x201c;Liquidity risk&amp;#x201d; in Note&amp;nbsp;29.&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt; &lt;/div&gt;</nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock>
  <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates &lt;br&gt;&lt;/br&gt;payable on demand &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;085 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;836 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 0.4% (2019: 0.5%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 5.0% (2019: 12.9%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock>
  <nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;22. Provisions and other current liabilities&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 749&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent considerations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 716&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&amp;nbsp;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 18 provides additional disclosures related to commitment for repurchase of own shares. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Provisions are based upon management&amp;#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for deductions from revenue&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement of the provisions for deductions from revenue:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement charge&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; January 1 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; related to &lt;br&gt;&lt;/br&gt; discontinued &lt;br&gt;&lt;/br&gt; operations&lt;sup&gt;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Effect of &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; and business &lt;br&gt;&lt;/br&gt; combinations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Payments/ &lt;br&gt;&lt;/br&gt; utilizations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Adjustments &lt;br&gt;&lt;/br&gt; of prior years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Change in &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; offset against &lt;br&gt;&lt;/br&gt; gross trade &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; December 31 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;560 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;739 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;053 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 167 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;597 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;940 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;272 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;094&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;931&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;294&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 99&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;183 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;193 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;28 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;659 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;698&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;348&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;590 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;158 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;541 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;356 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 83 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;555 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;109 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&amp;nbsp;227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;672&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;567&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring provisions movements&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, additions to provisions of USD&amp;nbsp;354 million were mainly related to the following reorganizations:&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Region Europe. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness that commenced in 2019 continued. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Group-wide initiatives to streamline Novartis Technical Operations through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, Novartis Business Services continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2019, additions to provisions of USD 492 million were mainly related to the following reorganizations:&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Latin America, and following the &lt;i&gt;Xiidra&lt;/i&gt; acquisition, its Ophthalmology field force in the US. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness. These initiatives include reduction in its headquarters, global functions and countries workforce, and the closure of its development center in Holzkirchen, Germany. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched the next phase of the new operating model to change outsourcing structures and transition activities to service centers. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;In 2018, additions to provisions of USD&amp;nbsp;534 million were mainly related to the following reorganizations:&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Innovative Medicines Division&amp;#x2019;s Oncology business unit initiative to streamline its organizational structure. The objective was to enhance agility and efficiency, resulting in an acceleration of operational execution. In addition, a program to reorganize the Japanese business model was launched. Region Europe transformed its approach to market in light of the changing product portfolio. The objective was to speed up patient access. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched an initiative to reorganize its organizational structure to achieve cost efficiencies by shifting activities to global service centers. &lt;/div&gt;</nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock>
  <nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 749&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent considerations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 716&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&amp;nbsp;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 18 provides additional disclosures related to commitment for repurchase of own shares. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock>
  <nvs:ProvisionsForReductionOfRevenueTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement charge&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; January 1 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; related to &lt;br&gt;&lt;/br&gt; discontinued &lt;br&gt;&lt;/br&gt; operations&lt;sup&gt;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Effect of &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; and business &lt;br&gt;&lt;/br&gt; combinations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Payments/ &lt;br&gt;&lt;/br&gt; utilizations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Adjustments &lt;br&gt;&lt;/br&gt; of prior years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Change in &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; offset against &lt;br&gt;&lt;/br&gt; gross trade &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; December 31 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;560 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;739 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;053 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 167 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;597 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;940 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;272 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;094&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;931&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;294&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 99&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;183 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;193 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;28 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;659 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;698&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;348&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;590 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;158 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;541 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;356 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 83 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;555 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;109 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&amp;nbsp;227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;672&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;567&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ProvisionsForReductionOfRevenueTableTextBlock>
  <nvs:RestructuringProvisionsMovementsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RestructuringProvisionsMovementsTableTextBlock>
  <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt; &lt;b&gt;23. Details to the consolidated statements of cash flows&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.1) Reversal of non-cash items and other adjustments from continuing operations&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;547&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;974&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 895&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;478 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;902 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 947&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;486&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net." &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.2) Total amount of taxes paid &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, the total amount of taxes paid was USD&amp;nbsp;1.9 billion, of which USD&amp;nbsp;1.8 billion was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, and USD&amp;nbsp;88 million was included within &amp;#x201c;Net cash flows used in investing activities from discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the total amount of taxes paid was USD&amp;nbsp;2.0 billion, of which USD&amp;nbsp;1.9 billion was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, USD&amp;nbsp;38 million was included within &amp;#x201c;Net cash flows from operating activities from discontinued operations,&amp;#x201d; and USD&amp;nbsp;79 million was included within &amp;#x201c;Net cash flows used in investing activities from discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2018, the total amount of taxes paid was USD&amp;nbsp;1.8 billion, of which USD&amp;nbsp;1.5 billion was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, USD&amp;nbsp;164 million was included within &amp;#x201c;Net cash flows from operating activities from discontinued operations,&amp;#x201d; and USD&amp;nbsp;139 million was included within &amp;#x201c;Net cash flows used in investing activities from continuing operations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities from continuing operations &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase) in inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;382&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease/(increase) in trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Decrease)/increase in trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 941&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 576&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, acquisitions and divestments of interests in associated companies included USD 12&amp;#xa0;855 million net of taxes (USD 12&amp;#xa0;994 million before taxes) from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.5) Cash flows arising from acquisitions and divestments of businesses, net&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;660&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 242&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;851&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows from divestments of businesses, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years. &lt;br&gt;&lt;/br&gt;In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million. &lt;br&gt;&lt;/br&gt;In 2018, USD 18 million represented the net cash inflows from divestments in previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.6) Reconciliation of liabilities arising from financing activities&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;261&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;56 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases continuing operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;471&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and lease liabilities related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;51 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 362&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;308&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;681&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For net cash flows used in investing activities from discontinued operations, see Note 30. &lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
  <nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;547&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;974&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 895&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;478 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;902 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 947&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;486&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net." &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock>
  <nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase) in inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;382&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease/(increase) in trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Decrease)/increase in trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 941&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 576&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock>
  <nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;660&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 242&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;851&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows from divestments of businesses, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years. &lt;br&gt;&lt;/br&gt;In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million. &lt;br&gt;&lt;/br&gt;In 2018, USD 18 million represented the net cash inflows from divestments in previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock>
  <nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;261&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;56 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases continuing operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;471&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and lease liabilities related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;51 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 362&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;308&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;681&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock>
  <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;24. Acquisitions of businesses&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Fair value of assets and liabilities arising from acquisitions of businesses&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 476&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 381&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 90&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;084&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Note 2 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020; &lt;i&gt;Xiidra&lt;/i&gt; and IFM Tre, Inc. in 2019; and AAA, AveXis and Endocyte in 2018. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD&amp;nbsp;74 million in 2020 (2019: USD 98 million, 2018: nil) is tax deductible. &lt;/div&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
  <nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 476&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 381&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 90&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;084&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock>
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;25. Post-employment benefits for associates&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&amp;#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 81% of the Group&amp;#x2019;s total DBO for post-employment benefit plans, are provided below. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Swiss-based pension plans represent the most significant portion of the Group&amp;#x2019;s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans from being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a predetermined factor for converting the accumulated savings account balance into a pension, and embedded death and disability benefits. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate&amp;#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&amp;#x2019;s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &amp;ndash; for the principal plans &amp;ndash; consists of representatives nominated by Novartis and the active insured associates. The boards of trustees are responsible for the plan design and asset investment strategy. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2020 the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment does not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The United States pension plans represent the second-largest component of the Group&amp;#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit obligations related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement losses/(gains) arising from changes in financial assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;791&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;132&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Plan assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus (incl. exchange rate differences)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reconciliation of the net liability from January 1 to December 31 is as follows:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;954&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less: net liability related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;788&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;007&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 15&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;408&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 516&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 1&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 1&amp;nbsp;136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;970&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;418&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 157&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 522&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 574&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine benefit obligations at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.0%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.1%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old male in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old female in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&amp;#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&amp;#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate&amp;#x2019;s savings account where the assumption on interest accrued changes in line with the discount rate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The impact of decreasing interest rates on a plan&amp;#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2020 year-end &lt;br&gt;&lt;/br&gt; defined benefit pension obligation &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 942&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 993&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;143&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate &lt;br&gt;&lt;/br&gt;assumed for next year &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6.3% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend &lt;br&gt;&lt;/br&gt;rate is assumed to decline &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches &lt;br&gt;&lt;/br&gt;the ultimate trend rate &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2020 and&amp;nbsp;2019:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(as a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; minimum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; maximum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The weighted average duration of the defined benefit obligation is 15.4 years (2019: 15.2 years).&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom and Germany. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2020, were as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post- &lt;br&gt;&lt;/br&gt; employment &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021 (estimated)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;198&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&amp;#x2013;2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;651&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 501&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 422&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 443&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For defined contribution plans for discontinued operations, see Note 30.&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <nvs:DisclosureOfDefinedBenefitPlansTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit obligations related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement losses/(gains) arising from changes in financial assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;791&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;132&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Plan assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus (incl. exchange rate differences)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDefinedBenefitPlansTableTextBlock>
  <nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;954&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less: net liability related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock>
  <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;788&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;007&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 15&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;408&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 516&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 1&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 1&amp;nbsp;136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;970&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;418&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
  <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 157&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 522&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 574&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
  <nvs:ScheduleOfAssumptionsUsedTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine benefit obligations at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.0%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.1%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old male in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old female in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfAssumptionsUsedTableTextBlock>
  <nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2020 year-end &lt;br&gt;&lt;/br&gt; defined benefit pension obligation &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 942&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 993&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;143&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock>
  <nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate &lt;br&gt;&lt;/br&gt;assumed for next year &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6.3% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend &lt;br&gt;&lt;/br&gt;rate is assumed to decline &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches &lt;br&gt;&lt;/br&gt;the ultimate trend rate &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
  <nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(as a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; minimum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; maximum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
  <nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock>
  <nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post- &lt;br&gt;&lt;/br&gt; employment &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021 (estimated)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;198&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&amp;#x2013;2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;651&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
  <nvs:ScheduleOfDefinedContributionPlansTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 501&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 422&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 443&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfDefinedContributionPlansTableTextBlock>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;26. Equity-based participation plans for associates&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based &lt;br&gt;&lt;/br&gt;participation plans &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 958 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;067 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 918 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based payment transactions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity-based participation plans can be separated into the following plans:&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Annual Incentive&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during February or March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share savings plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Associates in certain countries and certain key executives worldwide are encouraged to invest their Annual Incentive in a share savings plan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Under the share savings plan, participants may elect to receive their relevant compensation fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Novartis operates share savings plans for which associates may only participate in one of the share savings plans in any given year. The most significant are listed below: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &amp;#x201c;Select&amp;#x201d; are not eligible to receive ESOP matching shares starting with the 2017 performance period. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&amp;#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e., one share awarded for each invested share). In the United States, both the LSSP award and the corresponding match are cash settled. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Novartis Group CEO, the other Executive Committee members from 2014, and the NTLs from 2016 are not eligible to participate in the share savings plans. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis equity plan &amp;#x201c;Select&amp;#x201d;&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The equity plan &amp;#x201c;Select&amp;#x201d; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &amp;#x201c;Select&amp;#x201d;. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The equity plan &amp;#x201c;Select&amp;#x201d; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tradable share options expire on their 10 &lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the 10 &lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &amp;#x201c;Select&amp;#x201d; outside North America&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 59.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All share options were granted at an exercise price that was equal to the closing market price of the Group&amp;#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&amp;nbsp;91.7. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table summarizes information about share options outstanding at December 31, 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &amp;#x201c;Select&amp;#x201d; for North America&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the ADR options during the period: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 61.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 60.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&amp;nbsp;92.2. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table summarizes information about ADR options outstanding at December 31, 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;ADR options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Performance Plan&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. Starting in 2019, for new grants the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Relative Performance Plan&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The LTRPP is an equity plan for the Novartis ECN and NTLs. The last grant under this plan was made in 2018. The LTRPP performance criteria are based on variables that can be observed in the market, which is the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies is calculated as described in the LTPP section above. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other share awards&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Selected associates, excluding the ECN members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, in 2020, 2019 and 2018, Board members received unrestricted shares as part of their regular compensation.&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of non-vested share movements&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Annual Incentive&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Share savings plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 95.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 349&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 64.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select outside North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Performance Plan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 85.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Relative Performance Plan &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Other share awards&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 74.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 78.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount. &lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based &lt;br&gt;&lt;/br&gt;participation plans &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 958 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;067 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 918 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based payment transactions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 59.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 61.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 60.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;ADR options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
  <nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Annual Incentive&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Share savings plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 95.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 349&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 64.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select outside North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Performance Plan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 85.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Relative Performance Plan &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Other share awards&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 74.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 78.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount. &lt;/div&gt;</nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
  <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;27. Transactions with related parties&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche (see Note 4). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;i&gt;Lucentis&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has licensed from Genentech/Roche the exclusive rights to develop and market &lt;i&gt;Lucentis&lt;/i&gt; outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales of &lt;i&gt;Lucentis&lt;/i&gt; products outside the United States. In 2020, &lt;i&gt;Lucentis&lt;/i&gt; sales of USD&amp;nbsp;1.9 billion (2019: USD&amp;nbsp;2.1 billion; 2018: USD&amp;nbsp;2.0 billion) were recognized by Novartis. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;i&gt;Xolair&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and Genentech/Roche are co-promoting &lt;i&gt;Xolair&lt;/i&gt; in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis markets &lt;i&gt;Xolair&lt;/i&gt; and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2020, Novartis recognized total sales of &lt;i&gt;Xolair&lt;/i&gt; of USD&amp;nbsp;1.3 billion (2019: USD&amp;nbsp;1.2 billion; 2018: USD&amp;nbsp;1.0 billion), including sales to Genentech/Roche for the United States market. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;i&gt;Luxturna&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for &lt;i&gt;Luxturna&lt;/i&gt; outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The net income for royalties, cost sharing and profit sharing arising out of the &lt;i&gt;Lucentis&lt;/i&gt;, &lt;i&gt;Xolair&lt;/i&gt; and &lt;i&gt;Luxturna&lt;/i&gt; agreements with Roche totaled USD&amp;nbsp;217 million in 2020 (net income in 2019: USD&amp;nbsp;101 million; net expense in 2018: USD&amp;nbsp;34 million). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, Novartis has several patent license, supply and distribution agreements with Roche. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis Pension Fund&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the years 2020, 2019 and 2018. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Executive Officers and Non-Executive Directors compensation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, there were 13 Executive Committee members (&amp;#x201c;Executive Officers&amp;#x201d;). There were 15 Executive Officers in 2019 and 17 Executive Officers in 2018, including those who stepped down. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The total compensation for Executive Committee members and the 14 Non-Executive Directors (13 in 2019 and 2018) using the Group&amp;#x2019;s accounting policies for equity-based compensation and pension benefits was as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 42.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 69.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 79.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 72.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, the IFRS compensation expense increased due to higher cash and other compensation. This increase in cash compensation is mainly attributable to ECN members who joined the ECN during 2019, as a result 2019 represented only a portion of their annual compensation. Other compensation increased on account of higher social security payments on vested equity-based compensation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During 2019, the IFRS compensation expense decreased due to lower cash buyout payments to new executive officers and the forfeiture of equity-based compensation as a result of the resignation of an executive officer. These effects were partially offset by higher equity based compensation of executive officers appointed over the last three years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Transactions with former members of the Board of Directors&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, 2019 and 2018, the following payments (or waivers of claims) were made to former Board members or to &amp;#x201c;persons closely&amp;#x201d; linked to them: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Vasella&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF&amp;nbsp;60&amp;#xa0;000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date. &lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <nvs:OfficerAndDirectorCompensationTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 42.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 69.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 79.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 72.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OfficerAndDirectorCompensationTableTextBlock>
  <nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Vasella&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock>
  <nvs:DisclosureOfCommitmentsAndContingenciesTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;28. Commitments and contingencies&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development commitments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into long-term research and development agreements with various institutions, which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2020, the Group&amp;#x2019;s commitments to make payments under those agreements, and their estimated timing, were as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 449&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 483&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 281&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;232&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition in November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. These agreements provide for potential milestones payments by Novartis that may be capitalized. Based on their estimated timing, the payments for these transactions are expected to amount to USD 549 million in 2021, USD 248 million in 2022, USD 160 million in 2023, USD 415 million in 2024, USD 515 million in 2025, USD 1&amp;#xa0;409 million later than 2025, for a total of USD 3&amp;#xa0;296 million. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Commitments for capital calls&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2020, the total uncalled capital commitments for the Group&amp;#x2019;s investments in funds amounts to USD 87 million. Note 29 contains further information on the Group&amp;#x2019;s investments in funds. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other commitments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Guarantees issued&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, Novartis AG is guarantor of the Group&amp;#x2019;s issued bonds, credit facilities and commercial paper programs. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingencies&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Group companies have to observe the laws, government orders and regulations of the country in which they operate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&amp;#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Corporation is a party to such an agreement, which will expire in 2025. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on these matters.&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the opinion of management, however, the outcome of these actions will not materially affect the Group&amp;#x2019;s financial position but could be material to the results of operations or cash flow in a given period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&amp;#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on environmental liabilities.&lt;/div&gt;</nvs:DisclosureOfCommitmentsAndContingenciesTextBlock>
  <nvs:DisclosureOfLeasingCommitmentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 449&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 483&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 281&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;232&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfLeasingCommitmentsTableTextBlock>
  <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;29. Financial instruments &amp;ndash; additional disclosures&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the carrying values of financial instruments by measurement categories as of December 31, 2020 and 2019. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;085&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 32&amp;nbsp;623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&amp;nbsp;31, 2020 and 2019. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&amp;nbsp;2020 and 2019. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying principal amount&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 151&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in marketable securities and in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows by currency contract or underlying principal amount the derivative financial instruments at December&amp;nbsp;31,&amp;nbsp;2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments effective for hedge accounting purposes&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At the end of 2020 and 2019, there were no open hedging instruments for anticipated transactions. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Fair value by hierarchy&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets carried at Level 1 fair value are equity and debt securities listed in active markets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives, and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;613&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;451&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;604&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 151 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 34 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 206 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income, including currency translation effects &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 33 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 40 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 116 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 488&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact from discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;48 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 106 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, there were several individually non-significant transfers of financial investments from Level 3 to Level 1 for USD&amp;nbsp;166 million (2019: USD&amp;nbsp;64 million), mainly due to initial public offerings of the invested companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other expense,&amp;#x201d; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 92 million and USD 427 million, respectively. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, fund investments and long-term financial investments by 10% positively or negatively, this would change the amounts recorded in the 2020 consolidated statement of comprehensive income by USD&amp;nbsp;104 million. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the most significant parameters for the Level&amp;nbsp;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2020 consolidated income statement by USD&amp;nbsp;260 million and USD&amp;nbsp;324 million, respectively. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Equity securities measured at fair value through other comprehensive income&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Except for the investment in Alcon Inc. with a fair value of USD 71 million at December 31, 2020 (2019: USD 382 million), these are made up of individually non-significant investments. At December 31, 2020, the Group holds 56 non-listed equity securities (December 31, 2019: 53) and 34 listed equity securities (December 31, 2019: 29) in this category with the following fair values: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 862&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no dividends recognized during 2020 and 2019 from these equity securities. In 2020, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&amp;nbsp;331 million were sold (2019: USD 976 million), and the USD&amp;nbsp;13 million gain on disposal (2019: USD 62 million gain) was transferred from other comprehensive income to retained earnings during 2020. In addition, in 2020, equity securities that were no longer considered strategic, with a fair value of USD&amp;nbsp;206 million (2019: USD&amp;nbsp;33 million), were sold, and the USD&amp;nbsp;137 million gain on disposal (2019: USD&amp;nbsp;33 million gain) was transferred from other comprehensive income to retained earnings (see Note 8). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Nature and extent of risks arising from financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Market risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates, and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&amp;#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Foreign currency exchange rate risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&amp;#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There is also a risk that certain countries could devalue their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the rules of IAS 29 &amp;#x201c;Financial reporting in Hyperinflationary Economies&amp;#x201d;. The hyperinflationary economies in which Novartis operates are Argentina and Venezuela. Venezuela was hyperinflationary for all years presented, and Argentina became hyperinflationary effective July 1, 2018, requiring retroactive implementation of hyperinflation accounting as of January 1, 2018. The impacts of applying IAS 29 were not significant in all years presented. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2020, long-term financial debt with a carrying amount of EUR&amp;nbsp;1.8 billion (USD&amp;nbsp;2.3 billion) (December 31, 2019: USD 2.1 billion), has been designated as a hedge instrument. During 2020, USD&amp;nbsp;201 million of unrealized loss (unrealized income in 2019: USD 44 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Commodity price risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&amp;#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group&amp;#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest rate risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Equity risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Credit risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade receivables over the entire holding period of the trade receivables. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s largest customer accounted for approximately 17% of net sales, and the second largest and third largest customers accounted for 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively).&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 12% and 6%, respectively, of the Group&amp;#x2019;s trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). There is no other significant concentration of customer credit risk. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Counterparty risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency system, CLS (Continuous Linked Settlement), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately 14.1%, 12.6% and 9.7%, respectively (2019: 12.6%, 10.4% and 8.3%, respectively). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Liquidity risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Management monitors the Group&amp;#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has two US commercial paper programs under which it can issue up to USD&amp;nbsp;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY&amp;nbsp;150 billion (approximately USD&amp;nbsp;1.5 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&amp;nbsp;4.3 billion under these three programs were outstanding as per December 31, 2020 (2019: USD&amp;nbsp;2.3 billion). Novartis further has a committed credit facility of USD&amp;nbsp;6.0 billion, which was renewed in September 2019. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2024 and was undrawn as per December 31, 2020, and December 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2019, Novartis entered into a short-term credit facility of USD 7 billion, with a maturity date of June 30, 2020 with a syndicate of banks. On January 7, 2020, Novartis borrowed USD 7 billion under the facility with interest based on the USD LIBOR. On February 14, 2020, Novartis repaid the full USD 7 billion initially borrowed. The facility expired on June 30, 2020. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as contingent considerations at December 31, 2020, and December 31, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;571 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;635 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;781&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;661&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;802&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;593&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;503&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 122 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;712&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;237&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;096&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;745&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 710&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;728&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;624&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Other contractual liabilities that are not part of management&amp;#x2019;s monitoring of the net debt or liquidity consist of the following items: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;82&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;647&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;639&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;383&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Capital risk management&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2020, Moody&amp;#x2019;s Investor Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Value at risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses a value at risk (VAR) computation to estimate the potential 10-day loss in the fair value of its financial instruments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A 10-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes all financial assets and financial liabilities as set forth in the table on page F-69, except: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Trade receivables&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Other current assets&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Long-term loans and receivables, advances and security deposits&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Contingent considerations&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Lease liabilities&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Commitment for repurchase of own shares&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Trade payables&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a &amp;#x201c;Delta Normal&amp;#x201d; model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These interrelationships are determined by observing interest rate movements, stock market movements and foreign currency rate movements over a 60-day period for the calculation of VAR amounts. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated potential 10-day loss in the fair value of the Group&amp;#x2019;s foreign currency positions (including foreign exchange translation risk), the estimated potential 10-day loss of its equity holdings, and the estimated potential 10-day loss in fair value of its interest rate-sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions), as calculated in the VAR model, are the following: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 587&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 199 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to interest rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 187&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The average, high and low VAR amounts are as follows:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 322&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 225 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 515 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 71 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 261 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 329 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 912 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 348&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 385&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 303&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 86 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 81 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 233 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 303 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 187 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group&amp;#x2019;s future results of operations or financial position. &lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
  <nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;085&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 32&amp;nbsp;623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
  <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying principal amount&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 151&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in marketable securities and in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
  <nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock>
  <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;613&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;451&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;604&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
  <nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 151 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 34 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 206 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income, including currency translation effects &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 33 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 40 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 116 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 488&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact from discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;48 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 106 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock>
  <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 862&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
  <nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;571 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;635 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;781&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;661&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;802&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;593&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;503&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 122 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;712&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;237&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock>
  <nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;096&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;745&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 710&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;728&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;624&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock>
  <nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;82&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;647&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;639&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;383&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock>
  <nvs:DisclosureOfTenDayLossFairValueVARModelTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 587&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 199 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to interest rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 187&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfTenDayLossFairValueVARModelTableTextBlock>
  <nvs:DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 322&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 225 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 515 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 71 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 261 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 329 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 912 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 348&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 385&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 303&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 86 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 81 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 233 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 303 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 187 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock>
  <ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;30. Discontinued operations&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Discontinued operations include the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1 and 2 for further details). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Consolidated income statement&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from &lt;br&gt;&lt;/br&gt;discontinued operations &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;777 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7&amp;nbsp;149 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income/(loss) before taxes from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net loss from discontinued operations &lt;br&gt;&lt;/br&gt;before gain on distribution of Alcon Inc. &lt;br&gt;&lt;/br&gt;to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Additional significant accounting policies&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The accounting policies mentioned in Note 1 were used for the reporting of discontinued operations. The following additional significant accounting policies were applicable to discontinued operations. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketing know-how&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon brand name&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Not amortized, &lt;br&gt;&lt;/br&gt; indefinite useful life &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Other expense" &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &amp;#x201c;Other income.&amp;#x201d; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net income &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Included in net income from discontinued operations are:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Balance sheet &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows used in investing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable &lt;br&gt;&lt;/br&gt;to the spin-off of the &lt;br&gt;&lt;/br&gt;Alcon business &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows from financing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD 89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net assets derecognized &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;858&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables, provisions and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets derecognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2. &lt;/div&gt;</ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory>
  <nvs:ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from &lt;br&gt;&lt;/br&gt;discontinued operations &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;777 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7&amp;nbsp;149 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income/(loss) before taxes from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net loss from discontinued operations &lt;br&gt;&lt;/br&gt;before gain on distribution of Alcon Inc. &lt;br&gt;&lt;/br&gt;to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock>
  <nvs:ConsolidatedIncomeStatementAdditionalInformationTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ConsolidatedIncomeStatementAdditionalInformationTableTextBlock>
  <nvs:BalanceSheetAdditionalInformationTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:BalanceSheetAdditionalInformationTableTextBlock>
  <nvs:CashFlowsUsedInInvestingActivitiesTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable &lt;br&gt;&lt;/br&gt;to the spin-off of the &lt;br&gt;&lt;/br&gt;Alcon business &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsUsedInInvestingActivitiesTableTextBlock>
  <nvs:DisclosureOfNetAssetsDerecognizedTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;858&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables, provisions and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets derecognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetAssetsDerecognizedTableTextBlock>
  <nvs:ScheduleOfDefinedContributionPlansTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfDefinedContributionPlansTableTextBlock>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;31. Events subsequent to the December 31, 2020, consolidated balance sheet date&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Significant transactions not closed as of January&amp;nbsp;25,&amp;nbsp;2021&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. For additional information see Note 28. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Significant transaction closed in January 2021&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In December 2020, Novartis entered into a business acquisition agreement that closed on January 21, 2021, with an estimated fair value purchase price of USD 235 million. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Dividend proposal for 2020 and approval of&amp;nbsp;the Group&amp;#x2019;s 2020 consolidated financial statements &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On January 25, 2021, the Novartis AG Board of Directors proposed the acceptance of the 2020 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2021. Furthermore, also on January 25, 2021, the Board proposed a dividend of CHF 3.00 per share to be approved at the Annual General Meeting on March 2, 2021. If approved, total dividend payments would amount to approximately USD 7.7 billion (2019: USD&amp;nbsp;7.0 billion), using the CHF/USD December 31, 2020, exchange rate. &lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="AR_D-CurrentYear">&lt;a name="anchorNote31"&gt;&lt;/a&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;32. Principal Group subsidiaries and&amp;#xa0;associated&amp;#xa0;companies&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &amp;#xad;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&amp;#xa0;25&amp;#xa0;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Soci&amp;#xe9;t&amp;#xe9; par actions SANDOZ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Algiers&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Argentina S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buenos Aires&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 906.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Austria GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kundl&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;EBEWE Pharma Ges.m.b.H Nfg. KG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Unterach am Attersee&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Bangladesh) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gazipur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon - Couvreur NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Puurs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Securities Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Services Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Triangle International Reinsurance Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trinity River Insurance Co Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 370&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioci&amp;#xea;ncias S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;S&amp;#xe3;o Paulo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz do Brasil Ind&amp;#xfa;stria Farmac&amp;#xea;utica Ltda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Camb&amp;#xe9;, PR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dorval, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Manufacturing Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Chile S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santiago de Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing Novartis Pharma Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals (HK) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hong Kong&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China Novartis Institutes for BioMedical Research Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Suzhou Novartis Technical Development Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Changshu&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai Novartis Trading Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz (China) Pharmaceutical Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Zhongshan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Colombia S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santaf&amp;#xe9; de Bogot&amp;#xe1;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz d.o.o. farmaceutska industrija&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Zagreb&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ecuador S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Quito&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cairo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 193.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.77%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Egypt Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New Cairo City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finland Oy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Espoo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Groupe France S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 903.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Saint-Genis-Pouilly&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&amp;nbsp;734&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CELLforCURE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Les Ulis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Levallois-Perret&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Deutschland GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Business Services GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Produktions GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz International GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1 A Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oberhaching&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;HEXAL AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Salutas Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barleben&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aeropharm GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rudolstadt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Hellas) S.A.C.I.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Metamorphosis / Athens&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Hungary Healthcare Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 545.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Hungary Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 883.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis India Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70.68%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;PT. Novartis Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Jakarta&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ireland Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Integrated Services Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ringaskiddy Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies EU Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Israel Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tel Aviv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (Italy) S.r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pozzilli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 119&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ciba-Geigy Japan Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aspen Japan K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Baltics SIA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riga&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investments S.&amp;#xe0; r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation (Malaysia) Sdn. Bhd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kuala Lumpur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 468.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Maroc SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Casablanca&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Netherlands B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;IDB Holland BV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Baarle-Nassau&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Almere&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 907&amp;nbsp;560&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis New Zealand Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Auckland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 820&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Norge AS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oslo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Pakistan) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Karachi&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Logistics), Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Panama City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Peru&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Biosciences Per&amp;#xfa; S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lima&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PEN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Philippines, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 298.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Philippines Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Poland Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Polska Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Strykow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Portugal, S.G.P.S., Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma - Produtos Farmac&amp;#xea;uticos, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xea;utica, Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 499&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services Romania S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bucharest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Targu-Mures&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Neva LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;St. Petersburg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;ZAO Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saudi Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riyadh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Singapore) Pte Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Singapore Pharmaceutical Manufacturing Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Asia Pacific Pharmaceuticals Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Slovakia s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bratislava&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 48.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Midrand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kempton Park&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Korea Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Seoul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.55%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications Iberica, S.L.U.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Catalana de Dispensacion sau (Cadisa)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Esplugues de Llobregat&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 450&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xe9;utica S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Madrid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 270&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Industrial Products S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Les Franqueses del Vall&amp;#xe9;s / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon Cusi, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;El Masnou / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Abadia Retuerta S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sard&amp;#xf3;n de Duero / Valladolid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Sverige AB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stockholm&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International Pharmaceutical Investment AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioventures AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Forschungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Kaderausbildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Mitarbeiterbeteiligungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Mensch und Umwelt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stiftung der Novartis AG f&amp;#xfc;r Erziehung, Ausbildung und Bildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Overseas Investments AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japat AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 350.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweizerhalle AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Muttenz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Stein AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stein&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 251&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweiz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ophthalmics AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fribourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications International SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Geneva&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33%/6% &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Taiwan) Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taipei&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Thailand) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bangkok&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 302.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saglik, Gida ve Tarim &amp;#xdc;r&amp;#xfc;nleri Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Farmanova Saglik Hizmetleri Ltd. Sti.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ila&amp;#xe7; Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Grup Saglik &amp;#xdc;r&amp;#xfc;nleri Ila&amp;#xe7;lari Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Gebze - Kocaeli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ukraine LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kyiv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Middle East FZE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dubai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Grimsby Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (UK &amp;amp; Ireland)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Neutec Pharma Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ziarco Group Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Frimley / Camberley&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Coalesce Product Development Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, Cambs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Capital Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis US Foundation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications USA, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Millburn, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bannockburn, IL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Technology LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Optogenetics Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CoStim Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Endocyte, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Navigate BioPharma Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Carlsbad, CA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;The Medicines Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amblyotech Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oriel Therapeutics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Durham, NC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fougera Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Melville, NY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Eon Labs, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vaccines and Diagnostics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Venezuela, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Caracas&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vietnam Company Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ho Chi Minh City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Fully consolidated Foundation &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
  <nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Soci&amp;#xe9;t&amp;#xe9; par actions SANDOZ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Algiers&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Argentina S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buenos Aires&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 906.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Austria GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kundl&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;EBEWE Pharma Ges.m.b.H Nfg. KG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Unterach am Attersee&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Bangladesh) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gazipur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon - Couvreur NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Puurs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Securities Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Services Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Triangle International Reinsurance Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trinity River Insurance Co Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 370&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioci&amp;#xea;ncias S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;S&amp;#xe3;o Paulo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz do Brasil Ind&amp;#xfa;stria Farmac&amp;#xea;utica Ltda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Camb&amp;#xe9;, PR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dorval, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Manufacturing Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Chile S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santiago de Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing Novartis Pharma Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals (HK) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hong Kong&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China Novartis Institutes for BioMedical Research Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Suzhou Novartis Technical Development Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Changshu&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai Novartis Trading Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz (China) Pharmaceutical Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Zhongshan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Colombia S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santaf&amp;#xe9; de Bogot&amp;#xe1;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz d.o.o. farmaceutska industrija&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Zagreb&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ecuador S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Quito&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cairo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 193.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.77%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Egypt Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New Cairo City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finland Oy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Espoo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Groupe France S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 903.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Saint-Genis-Pouilly&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&amp;nbsp;734&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CELLforCURE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Les Ulis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Levallois-Perret&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Deutschland GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Business Services GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Produktions GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz International GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1 A Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oberhaching&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;HEXAL AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Salutas Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barleben&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aeropharm GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rudolstadt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Hellas) S.A.C.I.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Metamorphosis / Athens&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Hungary Healthcare Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 545.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Hungary Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 883.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis India Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70.68%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;PT. Novartis Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Jakarta&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ireland Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Integrated Services Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ringaskiddy Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies EU Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Israel Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tel Aviv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (Italy) S.r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pozzilli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 119&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ciba-Geigy Japan Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aspen Japan K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Baltics SIA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riga&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investments S.&amp;#xe0; r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation (Malaysia) Sdn. Bhd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kuala Lumpur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 468.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Maroc SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Casablanca&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Netherlands B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;IDB Holland BV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Baarle-Nassau&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Almere&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 907&amp;nbsp;560&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis New Zealand Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Auckland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 820&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Norge AS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oslo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Pakistan) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Karachi&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Logistics), Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Panama City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Peru&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Biosciences Per&amp;#xfa; S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lima&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PEN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Philippines, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 298.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Philippines Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Poland Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Polska Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Strykow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Portugal, S.G.P.S., Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma - Produtos Farmac&amp;#xea;uticos, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xea;utica, Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 499&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services Romania S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bucharest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Targu-Mures&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Neva LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;St. Petersburg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;ZAO Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saudi Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riyadh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Singapore) Pte Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Singapore Pharmaceutical Manufacturing Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Asia Pacific Pharmaceuticals Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Slovakia s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bratislava&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 48.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Midrand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kempton Park&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Korea Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Seoul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.55%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications Iberica, S.L.U.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Catalana de Dispensacion sau (Cadisa)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Esplugues de Llobregat&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 450&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xe9;utica S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Madrid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 270&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Industrial Products S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Les Franqueses del Vall&amp;#xe9;s / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon Cusi, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;El Masnou / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Abadia Retuerta S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sard&amp;#xf3;n de Duero / Valladolid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Sverige AB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stockholm&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International Pharmaceutical Investment AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioventures AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Forschungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Kaderausbildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Mitarbeiterbeteiligungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Mensch und Umwelt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stiftung der Novartis AG f&amp;#xfc;r Erziehung, Ausbildung und Bildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Overseas Investments AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japat AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 350.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweizerhalle AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Muttenz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Stein AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stein&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 251&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweiz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ophthalmics AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fribourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications International SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Geneva&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33%/6% &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Taiwan) Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taipei&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Thailand) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bangkok&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 302.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saglik, Gida ve Tarim &amp;#xdc;r&amp;#xfc;nleri Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Farmanova Saglik Hizmetleri Ltd. Sti.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ila&amp;#xe7; Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Grup Saglik &amp;#xdc;r&amp;#xfc;nleri Ila&amp;#xe7;lari Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Gebze - Kocaeli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ukraine LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kyiv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Middle East FZE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dubai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Grimsby Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (UK &amp;amp; Ireland)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Neutec Pharma Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ziarco Group Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Frimley / Camberley&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Coalesce Product Development Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, Cambs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Capital Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis US Foundation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications USA, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Millburn, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bannockburn, IL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Technology LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Optogenetics Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CoStim Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Endocyte, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Navigate BioPharma Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Carlsbad, CA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;The Medicines Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amblyotech Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oriel Therapeutics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Durham, NC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fougera Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Melville, NY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Eon Labs, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vaccines and Diagnostics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Venezuela, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Caracas&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vietnam Company Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ho Chi Minh City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Fully consolidated Foundation &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2030</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2050</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2028</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&amp;#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock>
  <nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;13. Financial and other non-current assets&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Financial assets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;577&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;979&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;901&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other non-current assets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 414&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock>
  <nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketing know-how&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon brand name&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Not amortized, &lt;br&gt;&lt;/br&gt; indefinite useful life &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Other expense" &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock>
  <dei:EntityRegistrantName contextRef="AR_D-CurrentYear">NOVARTIS AG</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="AR_D-CurrentYear">0001114448</dei:EntityCentralIndexKey>
  <dei:DocumentType contextRef="AR_D-CurrentYear">20-F</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="AR_D-CurrentYear">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="AR_D-CurrentYear">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="AR_D-CurrentYear">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer contextRef="AR_D-CurrentYear">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="AR_D-CurrentYear">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="AR_D-CurrentYear">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="AR_D-CurrentYear">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="AR_D-CurrentYear">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="AR_D-CurrentYear">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityInteractiveDataCurrent contextRef="AR_D-CurrentYear">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityShellCompany contextRef="AR_D-CurrentYear">false</dei:EntityShellCompany>
  <dei:EntityEmergingGrowthCompany contextRef="AR_D-CurrentYear">false</dei:EntityEmergingGrowthCompany>
  <dei:DocumentAnnualReport contextRef="AR_D-CurrentYear">true</dei:DocumentAnnualReport>
  <dei:DocumentShellCompanyReport contextRef="AR_D-CurrentYear">false</dei:DocumentShellCompanyReport>
  <dei:DocumentTransitionReport contextRef="AR_D-CurrentYear">false</dei:DocumentTransitionReport>
  <dei:IcfrAuditorAttestationFlag contextRef="AR_D-CurrentYear">true</dei:IcfrAuditorAttestationFlag>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Soci&#xE9;t&#xE9; par actions SANDOZ</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Algiers</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Algeria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Argentina S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Buenos Aires</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Argentina</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Pty Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Austria GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kundl</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">EBEWE Pharma Ges.m.b.H Nfg. KG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Unterach am Attersee</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Bangladesh) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Gazipur</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bangladesh</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma NV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz NV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Alcon - Couvreur NV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Puurs</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Investment Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Securities Investment Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finance Services Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Triangle International Reinsurance Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Trinity River Insurance Co Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Bioci&#xEA;ncias S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">S&#xE3;o Paulo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz do Brasil Ind&#xFA;stria Farmac&#xEA;utica Ltda.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Camb&#xE9;, PR</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals Canada Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dorval, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Canada Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Boucherville, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Chile S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Santiago de Chile</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Chile</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Beijing Novartis Pharma Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Beijing</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals (HK) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hong Kong</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Changshu</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Shanghai Novartis Trading Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Zhongshan</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis de Colombia S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Santaf&#xE9; de Bogot&#xE1;</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Colombia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz d.o.o. farmaceutska industrija</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Zagreb</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Croatia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis s.r.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz s.r.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Healthcare A/S</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz A/S</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ecuador S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Quito</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ecuador</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cairo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Egypt Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">New Cairo City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finland Oy</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Espoo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Finland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Groupe France S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma S.A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Saint-Genis-Pouilly</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">CELLforCURE</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Les Ulis</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz S.A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Levallois-Perret</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Business Services GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Produktions GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz International GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">1 A Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Oberhaching</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">HEXAL AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Salutas Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Barleben</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Aeropharm GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Rudolstadt</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Hellas) S.A.C.I.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Metamorphosis / Athens</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Greece</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Hungary Limited Liability Company</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis India Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Healthcare Private Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Private Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">PT. Novartis Indonesia</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Jakarta</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Indonesia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ireland Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ringaskiddy Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ringaskiddy, County Cork</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farma S.p.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Origgio</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications (Italy) S.r.l.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Pozzilli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz S.p.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Origgio</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma K.K.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ciba-Geigy Japan Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz K.K.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Baltics SIA</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Riga</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Latvia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Investments S.&#xE0; r.l.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finance S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Corporation (Malaysia) Sdn. Bhd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kuala Lumpur</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Malaysia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farmac&#xE9;utica, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Maroc SA</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Casablanca</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Morocco</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Netherlands B.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma B.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">IDB Holland BV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Baarle-Nassau</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz B.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Almere</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis New Zealand Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Auckland</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">New Zealand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Norge AS</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Oslo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Norway</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma (Pakistan) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Karachi</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Pakistan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma (Logistics), Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Panama City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Panama</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Biosciences Per&#xFA; S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Lima</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Peru</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Poland Sp. z o.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Polska Sp. z o.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Lek S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Strykow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Portugal, S.G.P.S., Lda.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farma - Produtos Farmac&#xEA;uticos, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Farmac&#xEA;utica, Lda.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Services Romania S.R.L.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bucharest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz S.R.L.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Targu-Mures</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Neva LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">St. Petersburg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">ZAO Sandoz</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Saudi Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Riyadh</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Saudi Arabia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Singapore) Pte Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Slovakia s.r.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bratislava</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Slovakia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Lek Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Midrand</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kempton Park</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Korea Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Seoul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">South Korea</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farmac&#xE9;utica, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Farmac&#xE9;utica S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Madrid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Les Franqueses del Vall&#xE9;s / Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Abadia Retuerta S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sard&#xF3;n de Duero / Valladolid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Sverige AB</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Stockholm</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sweden</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis International AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Holding AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis International Pharmaceutical Investment AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Bioventures AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Forschungsstiftung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Stiftung f&#xFC;r Kaderausbildung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Mitarbeiterbeteiligungsstiftung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Stiftung f&#xFC;r Mensch und Umwelt</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Overseas Investments AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japat AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Services AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Schweizerhalle AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Muttenz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Stein AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Stein</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Schweiz AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ophthalmics AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Fribourg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications International SA</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Geneva</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Pharmaceuticals AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Roche Holding AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Taiwan) Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Taipei</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Taiwan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Thailand) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bangkok</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Thailand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Farmanova Saglik Hizmetleri Ltd. Sti.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Ila&#xE7; Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Gebze - Kocaeli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Ukraine LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kyiv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ukraine</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Middle East FZE</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dubai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Arab Emirates</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis UK Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals UK Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Grimsby Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ziarco Group Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Frimley / Camberley</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finance Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Capital Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Services, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis US Foundation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications USA, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Millburn, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Gene Therapies, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bannockburn, IL</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Technology LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">CoStim Pharmaceuticals Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Endocyte, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Navigate BioPharma Services, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Carlsbad, CA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Oriel Therapeutics, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Durham, NC</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Fougera Pharmaceuticals Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Melville, NY</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Eon Labs, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Vaccines and Diagnostics, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis de Venezuela, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Caracas</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Venezuela</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Manufacturing Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Boucherville, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Alcon Cusi, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">El Masnou / Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China Novartis Institutes for BioMedical Research Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Suzhou Novartis Technical Development Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz (China) Pharmaceutical Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Deutschland GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Hungary Healthcare Limited Liability Company</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Integrated Services Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ringaskiddy, County Cork</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Gene Therapies EU Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Israel Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tel Aviv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Israel</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Aspen Japan K.K.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Healthcare Philippines, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Philippines Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Asia Pacific Pharmaceuticals Pte Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications Iberica, S.L.U.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Esplugues de Llobregat</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Catalana de Dispensacion sau (Cadisa)</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Industrial Products S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Stiftung der Novartis AG f&#xFC;r Erziehung, Ausbildung und Bildung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Saglik, Gida ve Tarim &#xDC;r&#xFC;nleri Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Grup Saglik &#xDC;r&#xFC;nleri Ila&#xE7;lari Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications (UK &amp; Ireland)</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Neutec Pharma Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Coalesce Product Development Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cambridge, Cambs</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Institutes for BioMedical Research, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Optogenetics Research, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">The Medicines Company</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Amblyotech Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Vietnam Company Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ho Chi Minh City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vietnam</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketing know-how&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon brand name&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Not amortized, &lt;br&gt;&lt;/br&gt; indefinite useful life &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Other expense" &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &amp;#x201c;Other income.&amp;#x201d; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net income &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Included in net income from discontinued operations are:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Balance sheet &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows used in investing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable &lt;br&gt;&lt;/br&gt;to the spin-off of the &lt;br&gt;&lt;/br&gt;Alcon business &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows from financing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD 89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net assets derecognized &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;858&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables, provisions and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets derecognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
</xbrli:xbrl>